# FIVE YEAR REPORT ON THE MEDICAL FOLLOW UP OF MARSHALLESE RECEIVING SPECIAL MEDICAL CARE RELATED TO 1954 BRAVO FALLOUT RADIATION (JANUARY 1992 - 1996)

By

Ashok N. Vaswani, M.D. And Jean E. Howard, M.D.

Brookhaven National Laboratory
Medical Department
Upton, New York 11973

DISTRIBUTION OF THIS DOCUMENT IS UNLEMED

MASTER

June 1999

Prepared for
U.S. Department of Energy
Assistant Secretary for Environment, Safety and Health
Office of Health

#### **DISCLAIMER**

This report was prepared as an account of work sponsored by an agency of the United States Government. Neither the United States Government nor any agency thereof, nor any of their employees, make any warranty, express or implied, or assumes any legal liability or responsibility for the accuracy, completeness, or usefulness of any information, apparatus, product, or process disclosed, or represents that its use would not infringe privately owned rights. Reference herein to any specific commercial product, process, or service by trade name, trademark, manufacturer, or otherwise does not necessarily constitute or imply its endorsement, recommendation, or favoring by the United States Government or any agency thereof. The views and opinions of authors expressed herein do not necessarily state or reflect those of the United States Government or any agency thereof.

## **DISCLAIMER**

Portions of this document may be illegible in electronic image products. Images are produced from the best available original document.

#### **FOREWORD**

As part of the United States atmospheric nuclear weapons testing program between 1946 and 1958, 23 nuclear devices were detonated at the Bikini Atoll and 43 nuclear devices were detonated at the Enewetak Atoll. A 1954 United States thermonuclear weapons test, code named "Bravo" was conducted at the Bikini Atoll and produced a nuclear yield much higher than expected. As a result, the levels and dispersion of the radioactive fallout from Bravo were significantly greater than originally expected, resulting in radioactive fallout on the inhabited atolls of Rongelap and Utrik. The Rongelap and Utrik inhabitants were evacuated from their contaminated atolls, within 48 and 72 hours, respectively, after the Bravo test. The original population directly exposed to the fallout from Bravo consisted of 241 individuals and 12 fetuses. Adsorbed dose estimates for the exposed population were on the order of 0.11 to 1.9 Gray (11 to 190 Rad) to the whole body and from 1.9 to 200 Gray (190 to 20,000 Rad) to the thyroid.

Public Law 99-239 mandated that the United States would "...continue to provide special medical care and logistical support thereto for the remaining 174 members of the population of Rongelap and Utrik who were exposed to radiation resulting from the 1954 United States thermonuclear Bravo test...". The Department of Energy (DOE) implemented this Congressional mandate, for the period of this report, through a contract with the Brookhaven National Laboratory.

The purpose of the Marshall Islands Medical Program is to provide medical care and treatment to the Congressionally-mandated groups of Rongelap and Utrik who were exposed to fallout from the 1954 Bravo test. As of December 1998, the original Congressionally-mandated population consisted of 130 individuals.

The program offers, on a voluntary basis, an annual physical examination to these individuals, as well as annual physical examinations to volunteer comparison individuals. Medical surveillance includes a complete annual physical examination (based on American Cancer Society criteria) by a variety of specialists including gastroenterologists, hematologists, obstetricians/gynecologists, endocrinologists, oncologists, radiologists, cardiologists, nephrologists, pulmonologists, and rheumatologists.

This, the 17<sup>th</sup> report of the Marshall Islands Program, provides information concerning the medical status of the 253 Marshallese exposed to the fallout from the 1954 Bravo test.

Frank Hawkins

Director

Office of International Health Programs

#### **DEDICATION AND APPRECIATION**

This report is dedicated to all of the patients who have participated for the past 44 years in the medical program. We wish to thank them for their voluntary participation in one of the longest running patient care programs in the history of medical practice, and sincerely appreciate their commitment. We wish them continued success in reaching their future health objectives.

The Marshall Islands Medical Program is deeply indebted to the many outstanding physicians who, despite the inevitable personal inconvenience, participated in the medical team visits of 1992-1996. It is fair to say that they were the heart of the program.

## **CONTENTS**

P	age
Introduction	1
Patient Groups	1
The Marshall Islands Medical Program Program Mandate Program Administration and Physician Volunteers Program Policies Interim Care Consultations and Educational Activities Program Oversight Program Operations and Procedures Staff	1 2 2 3 3
Clinical Follow Up for the 5 Year Period Patient Participation Examinations and Laboratory Testing Specific Medical Conditions - Thyroid Nodules Histologic Definitions Sigmoidoscopies and GI Workup Referrals to the Tertiary Medical Care Center and to the RMI Government Patient Deaths During 1992-1996	5 6 8 . 11
Bibliography	. 17
Epilogue	. 18
Appendix A - List of Participating Physicians and Technical Staff	A-1
Appendix B - Results of CBCs and Laboratory Chemistries Using Patient ID Numbers	B-1

# **5-Year Report**

#### INTRODUCTION

This is the 17th and final report of the Marshall Islands Medical Program as carried out by the Brookhaven National Laboratory (BNL). The purpose of these publications has been to provide information on the medical status of 253 Marshallese exposed to radiation fallout in 1954. The medical program fulfills a commitment to disclose unique medical information relevant to public health. Details of the Bravo thermonuclear accident that caused the exposure have been published. A 1955 article in the Journal of the American Medical Association, which described the acute medical effects on the population that required special medical care, remains a definitive and relevant description of events (Cronkite et al., 1955).

Marshallese participation in this Congressionally mandated program is voluntary. Throughout the 44 years of the program, each participating individual's relevant medical findings, laboratory data, disease morbidity, and mortality have been published in the BNL reports in a manner preserving patient confidentiality. In each report, there has been an attempt to interpret these findings and to infer the role of radiation exposure in their development. An equally important aspect of the reports has been the presentation of data that allows for analyses of the medical consequences of the Marshallese exposure.

#### PATIENT GROUPS

The Marshallese population mandated (the mandated group) under the Compact of Free Association Act (P.L. 99-239), originally comprised 64 persons on Rongelap Atoll who had received an estimated 190 rad (190 cGy) of whole-body external gamma radiation, 18 on Ailinginae Atoll (Sifo Island) who received 110 rad (110 cGy), and 159 on Utrik Atoll who received 11 rad (11 cGy). For the purpose of this report, the Rongelap and Ailinginae patients are treated as one and referred to as the Rongelap group because the persons on Ailinginae were Rongelap inhabitants temporarily residing on this nearby atoll. The differences in the dose due to exposure to radioiodines were dependent on the relative distance of the atolls and islands from the Bravo test site. At the time of the accident, there were 12 pregnant women (3 on Rongelap, 1 on Ailinginae, and 8 on Utrik), each of whom received whole-body doses equivalent to doses received by the other inhabitants of their respective atolls. The twelve individuals who were exposed in utero were also considered part of the mandated group after

birth. Due to the presence of radioiodines in the fallout, the thyroid gland received an exposure that was much greater than the whole-body dose; the dose due to radioiodine exposure was a function of the individual's age at the time of exposure (Lessard et al., 1985).

In 1957, a group of 86 volunteer comparison individuals from Rongelap were selected to match the mandated group by gender and age (Conard et al., 1958). A second volunteer comparison group was subsequently initiated and matched by age and gender to the mandated group. The second comparison group was statistically similar to the Rongelap and Utrik groups. Both these groups are listed in this report as the comparison group. As in previous reports, it is the expanded volunteer non-mandated group which is used for comparisons of year-to-year medical events and causes of death. The survival rates of the mandated and volunteer unmandated groups are also compared.

#### THE MARSHALL ISLANDS MEDICAL PROGRAM

#### Program mandate:

The mandate of the program, as required by the U.S. Congress in 1980 (PL 96-205, Sec. 106 (a)), specified "...a program of medical care and treatment....for any injury, illness, or condition which may be the result directly or indirectly of such nuclear weapons testing program." Subsequently, in 1985, the Compact of Free Association between the U.S. and the Republic of the Marshall Islands (RMI) allowed the Marshallese to manage their own radiation injury compensation. However, in response to a request from the RMI, a subsidiary agreement permitted the BNL medical program to continue supplemental local health care for the mandated persons. Specifically, P.L. 99-239 states: "..the President....shall continue to provide special medical care and logistical support thereto for the remaining 174 members of the population of Rongelap and Utrik who were exposed to radiation resulting from the 1954 United States thermonuclear Bravo test, pursuant to Public Laws 95-134 and 96-

#### Program administration and physician volunteers:

The Marshall Islands Medical Program and its medical missions to the Marshall Islands were based at BNL since the inception of the program. The program's staff included a physician-director, an administrator, a BNL medical associate, and a Marshallese laboratory technician on Ebeye. The

medical missions were usually conducted in the spring and fall of each year; a variety of physicians were recruited to be part of the medical team. They were skilled volunteers, primarily selected from the staff of university-affiliated or government hospitals, and often had past experience with the program. At the time of the initial medical examination, Dr. Jacob Robbins, (Chief of the Endocrinology Section, Genetics and Biochemistry Branch, National Institutes of Health, Bethesda, MD.) provided guidance and management of the program's thyroid disease aspects.

Currently, Bechtel Nevada (under DOE contract) provides logistical support to the medical program. Previously, this support had been conducted by Raytheon Services Nevada until 1995. Logistical support involves all transport, housing, and accommodation arrangements for the staff and patients traveling between Honolulu, Hawaii and the entire Marshall Islands. Additionally, Bechtel Nevada was involved in converting the program from a vessel-based to a land-based program, working closely with the U.S. Army Kwajalein Atoll personnel and executing the necessary structural changes to the medical trailers (adjacent to Kwajalein Hospital) which currently houses the medical program. The proximity to Kwajalein Hospital has eliminated the need for duplicate services that were necessary for the vessel-based program. Since 1996, all radiologic services have been performed by the Kwajalein personnel; most of the routine hematology is now completed in the Kwajalein Hospital On request, the Marshall Islands laboratory. government provides nurses, translators, and other health care workers. Bechtel Nevada offices on Majuro and Kwajalein oversee local staff.

#### Program policies:

The Marshall Islands Medical Program was created for the benefit of the mandated Marshallese patients. It was a program of radiation-related disease surveillance consisting of periodic examination and treatment of disease. Periodically, clinical investigations had been carried out by the program; the intent of these investigations was to identify present or future threats to the health of the mandated Marshallese patients, hopefully in time to prevent or limit morbidity and mortality. Based on the medical program's early findings of numerous thyroid nodules in the mandated group, thyroid hormone suppression was initiated for the Rongelap group in 1965 in an attempt to prevent thyroid It is possible that this nodules/carcinoma.

prophylaxis has met with some success. As discussed in detail later in this paper, thyroid ultrasound examinations were initiated in 1994 as a means of detecting early changes in the evolution of thyroid nodules.

The Marshall Islands Medical Program provided medical care to the mandated group by visiting the islands where most subjects resided: namely, Majuro, Ebeye, Mejatto and Utrik. In addition, the medical team provided health care monitoring and surveillance for all comparison group patients.

Any individual of the special medical care group whose medical findings suggested a malignant neoplasm or other radiation-related disease was referred to secondary or tertiary medical facilities for definitive evaluation and therapy. Those persons with problems that could be effectively managed on Majuro were referred to the Marshallese Health Services. Those requiring a more extensive evaluation were referred to hospitals in Honolulu. Individuals needing referral for non-radiation related problems were sent to the Marshallese Health Service on their island of residence, where treatment was initiated.

#### Interim care:

During the period between the two medical missions conducted by the Marshall Islands Medical Program, the continuity of health care for the mandated and comparison groups was carried out by the Marshallese Government Health Services, which is a national health care program involving two hospitals on the most populated islands, Majuro and Ebeye. A network of clinics scattered over some 20 atolls also assisted in health care. This network of health care providers, which included physicians and public health care workers, served the entire population of the Marshall Islands, which numbers over 64,000 people. Interim care was also provided by the physicians and health workers belonging to the 177 Health Care Program. The 177 Health Care Program, operated by the Sisters of Mercy, is currently responsible for the health care of an estimated 12,600 people. Based on Majuro Atoll, the 177 Health Care Program provides primary health care to the four atoll communities of Enewetak, Rongelap, Bikini and Utrik.

At the end of each medical session, with the permission of the examinees, copies of all examination and laboratory data were delivered to the Marshall Islands Health Service hospitals on Majuro and Ebeye and to the physicians of the 177 Health Care Program. In addition, copies of physical examinations and laboratory test results completed at Kwajalein were provided to the patients themselves, thus facilitating the exchange of thorough medical information.

#### Consultations and educational activities:

While providing medical surveillance to the mandated and comparison groups, the medical program physicians came into contact with family members of the mandated and other island inhabitants. It was the policy of the Department of Energy to support the medical program in its efforts to provide consultations and limited treatment to these individuals on the basis of humanitarian need and as resources permitted. Consultations were initially provided by the program staff as they visited islands during the course of the two missions. When the program became land-based at Kwajalein, consultative services were provided almost exclusively for the residents of Ebeye and the Marshallese employees working at the U.S. Army Kwajalein Atoll base on Kwajalein. The medical program also provided in-house consultations by sending specialists to the Ebeye hospital to accompany local Ebeye physicians on rounds. During each mission, lectures given by team physicians contributed to the continuing medical education of the Kwajalein and Ebeye hospital staff and physicians.

#### Program oversight:

The Marshall Islands Medical Program, as a satellite clinic of the Clinical Research Center, Brookhaven National Laboratory, was accredited by the Joint Commission on Accreditation of Healthcare Organizations, a nationwide organization setting and monitoring performance standards for institutions dispensing medical care. By voluntarily participating in the accreditation process, the Marshall Islands Medical Program received a valuable and impartial external review of its policies and procedures, as well as an assessment of the provided services. Laboratory and radiological services, medical records, patient satisfaction, pharmaceutical services, and clinical competence of physicians were among the many items reviewed by the Joint Commission. Guidelines and questionnaires were developed to generate the information necessary for compliance with the Joint Commission's requirements.

#### Program operations and procedures:

Since the mandated group needed to be considered at increased risk for malignant disease (as a late complication of radiation exposure), the medical program installed a cancer-oriented annual health evaluation. The examinations followed the

guidelines of the American Cancer Society and included a medical history, complete physical examination, annual pelvic examinations and Papanicolaou smears (PAP smears) on women, annual mammography (offered to all women forty years of age or older), annual prostate specific antigen (PSA) tests on all males, blood count, urinalysis, stool testing for occult blood, and flexible sigmoidoscopy (every three years for persons fifty years of age or older.) Advice on self-detection of lesions and on decreasing the risk factors for cancer was provided by printed informational materials and discussions with the public health personnel who were part of the medical team. The public health personnel also developed informational materials in the local language documenting the prevention of common communicable diseases, such as tuberculosis and acquired immune deficiency syndrome, and non-radiogenic diseases, such as diabetes and hypertension. Ophthalmologic examinations were provided by the Marshall Islands Health Services since ophthalmologists had not accompanied the medical team in the past four years. As mandated individuals were also considered at increased risk for certain endocrine problems, they received annual thyroid function blood tests and thyroid examinations by a specialist in endocrinology or thyroid surgery. Since 1994, when the thyroid ultrasound program was initiated, ultrasound-guided fine needle aspirations (FNAs) had been included as part of the surveillance, and were performed on patients with palpable nodules, or nodules greater than 10 mm in diameter. Annually, thyroglobulin determinations were made on all subjects as clinical factors warranted, such as a history of thyroid cancer, or post thyroid lesion surgery. Other serologic tests were performed on a regular basis in an attempt at early detection of malignant nonthyroidal lesions. These included serum protein electrophoresis, calcium, prolactin, and alphafetoprotein levels on persons known to have positive Hepatitis B surface antigens. There was also ongoing immune competency monitoring, since the mandated persons may have been at increased risk of acquiring infectious diseases.

While the program was vessel-based, special procedures (such as thyroid ultrasound and sigmoidoscopy or colonoscopy) were performed in two hospital rooms dedicated to these purposes. Some patients were examined at dispensaries on Mejatto and Utrik, and home visits were arranged for the elderly and infirm who preferred not to be transported to the ship or flown to Kwajalein for the complete examination.

Clinical laboratory services for the missions were performed by several BNL technicians with support

from personnel of the Kwajalein Hospital and Health Services of the RMI. Routine hematology testing was performed on a J.T. Baker 5000 electronic counter and, beginning in the fall of 1989, on a Serono Baker 9000 RX automatic 8-parameter cell counter. Leukocyte differentials and platelet counts were part of each evaluation. Clinical chemistry tests were performed on Eastman Kodak EktaChem DT60, DTSC or DTE analyzers. These analyzers provided a wide variety of basic chemistry tests with a small amount of disposable waste. Urinalysis included a dipstick examination and, when indicated, microscopic analysis. Stool exams were performed at physicians' request for identification of parasites and occult blood.

Roentgenographic services on board the vessel, Offshore Venture, were provided using a dedicated (beginning 1995, mammography unit in mammography was performed at the U.S. Army Hospital on Kwajalein Island) and a standard x-ray unit manufactured by the Bennett Corporation, Long Island, NY. X-ray interpretation was done at the time of examination. However, if no radiologist was part of the medical team, the x-ray films were returned to BNL and then referred to a consultant radiologist, Dr. Harold Atkins at the State University of New York, Stony Brook. Once the program was land-based, radiographic tests and mammograms were performed using the GE units located at Kwajalein Hospital. A volunteer radiologist physician always accompanied the medical team, eliminating the need for x-rays to be sent to the U.S. for review.

A portable battery powered electrocardiograph machine was available. Electrocardiogram interpretation was done at the time of examination, with a copy often given to the patient. All electrocardiograms were subsequently returned to BNL and then referred to a consultant cardiologist (Dr. M. Zema) at Brookhaven Memorial Hospital on Long Island, NY, for definitive analysis.

A General Electric thyroid ultrasound machine was purchased for the detection of thyroid nodules and used for ultrasound-guided fine needle aspiration of thyroid nodules suspected of malignancy. A second ultrasound machine (a Hewlett-Packard Sonos 100) was available for assessment of such diverse items or factors as abdominal pain, hematuria, gestational age, and cardiac disease. It was used only under the guidance of a radiologist or subspecialist physician with expertise in ultrasound examination.

Sera collected during the routine physical examinations were analyzed at the time of patient examination, as clinically indicated. The remainder

were frozen for further testing upon return to BNL. The latter tests were performed at commercial laboratories. One of these referral laboratories, Labcorp, of Garden City, New York carried out all routine and special chemistries involving thyroid hormone analysis. Labcorp also was responsible for the PAP smears. All other cytology and pathology was sent to the Pathology Department, State University of New York at Stony Brook, for analysis of thyroid biopsy specimens and special cytology for GI or GYN biopsy specimens.

The samples analyzed by the BNL staff were subject to a laboratory environment with quality control and quality assurance and involved routine calibration, maintenance, and monitoring of all instrumentation. Daily tri-level analysis of reference materials was performed on the hematology analyzer. The chemistry analyzer was calibrated prior to each mission, and bilevel quality control samples were run on all analyses. Pursuant to the enactment of the Clinical Laboratory Improvement Analysis Legislation, the program subscribed to Wisconsin State Hygiene Laboratory proficiency testing. When necessary, laboratory instrumentation was inspected and repaired by company service representatives. instrumentation, such as sphygmomanometers, electrocardiograph machines, and doppler units, was periodically calibrated and had routine preventative maintenance performed between missions at BNL.

Additional quality assurance methods included the use of patient questionnaires. These questionnaires translated into Marshallese - solicited criticism and advice for improving the medical program's operation. One important quality assurance mechanism was the mission's use of volunteer physicians from across the United States. The on-site advice, commentary, and criticism of these physicians helped to maintain the high standards of patient care. Additionally, all physicians participated in on-site peer review. Finally, the results of these and other mechanisms of quality assurance were reviewed by the BNL Clinical Research Center Quality Assurance and Care Committee. Also included in that review was the appropriateness of using anti-infective agents; a certified medical records consultant randomly reviewed approximately 20 percent of the records for accuracy and completeness.

#### Staff:

The volunteer medical staff was drawn from excellent medical centers and private practices throughout the United States. During the past few years, each mission was successfully manned by a core of physicians comprising the medical director (internal

medicine), an endocrinologist, another internist or family practitioner, a gynecologist and a radiologist. These physicians provided the program with a wide range of up-to-date clinical experience and perspective that contributed to better patient care. Appendix A lists the physicians by their respective specialties, as well as medical team personnel involved in the 1992-1996 missions.

#### CLINICAL FOLLOW-UP FOR THE 5 YEAR PERIOD

#### Patient participation:

As previously indicated, patient participation in the Marshall Islands Medical Program was entirely voluntary. Prior to the arrival of the medical team in the Marshall Islands, local newspapers and radio stations announced the imminent arrival of the medical groups and the location of the proposed examination sites. These announcements permitted the patients to make appropriate arrangements for their visits. For the first four years of this reporting period - when the program was vessel-based - the boat docked in Majuro port, where patients were scheduled for their medical evaluations. At the end of approximately one week, the Offshore Venture departed for Kwajalein. The vessel, with on-board medical facilities, docked at Ebeve, where the medical staff evaluated the mandated and comparison groups residing on Ebeye. The boat also made a two-week trip to the outer islands of Utrik and Mejatto. The total duration of the mission was approximately 4-5 weeks.

#### 1992-1996 Marshall Islands Medical Program

At the beginning of the 1992 reporting period, there were an estimated 154 patients in the mandated groups and 113 patients in the volunteer groups. These patients were given the opportunity to return on an annual basis; the actual percentage of mandated and comparison patients who availed themselves of these services is listed in Table 1. Patient acceptance of the transference of care from vessel-based to landbased was enthusiastic, as patients were afforded more flexibility in scheduling appointments. During vessel-based examinations, a patient who had to be seen in Majuro only had a total of seven days to schedule a visit. Since the land-based program lasted approximately four weeks, patients had more time to schedule visits and were more likely to complete a physical examination for that year. Overall, the acceptance of the land-based program by all of the patients was extremely positive. They were able to receive reports of their most recent blood tests done on Kwajalein. At the end of each mission, copies of these reports were also sent to the respective primary care physicians on Ebeye, Majuro or the outer islands.

Patients who reside outside of the Marshall Islands are not necessarily represented in the patient group examined during the five-year period. These patients are predominantly located on the islands of Hawaii; some have migrated to mainland USA. All patients were notified about pending missions; however, they may or may not have availed themselves of these services. Appropriate arrangements had been made for these non-resident patients residing in Hawaii to receive care at a tertiary center in Honolulu or elsewhere.

#### Post-1996 Marshall Islands Medical Program

As previously noted, since 1996 the program has been land-based and located at Kwajalein Hospital. Two trailers, refurbished for the purpose of the medical program, included a male examining room, a female examining room, a gynecological examining room, an endocrinology area, laboratory and pharmacy facilities, a waiting area for the patients, and a room for administrative purposes. Two special procedure rooms were leased from the hospital — one for performing sigmoidoscopy/colonoscopy procedures and one for a thyroid ultrasound unit.

In addition, the hospital laboratory and radiological services were made available for CBC, chemistries and urinalysis and other routine tests. The hospital technician who performed mammograms and x-rays was also available to schedule these tests. Thyroid ultrasound was done by a specially trained technician who had been subcontracted for each of the medical missions for the past five years.

#### Examinations and laboratory testing:

Generally, in keeping with the preservation of cultural sensitivities and individual wishes, male patients were examined by a male physician and female patients by a female physician. Blood was drawn for routine and special chemistries, and other tests deemed necessary were conducted at the hospital. The land-based program allowed for greater ease in obtaining tests and prevented duplication of the laboratory equipment or personnel.

It should be noted that, once the mission was landbased at Kwajalein, the routine and screening mammogram procedures increased dramatically, due to the availability of an approved mammography site.

<b>TABLE 1.</b> Total number of patients seen each year between 1992 and 1
----------------------------------------------------------------------------

GROUP	Number	1992	1993	1994	1995	1996
Mandated*	154	92%	84%	83%	83%	84%
Comparison	113	79%	65%	61%	55%	79%

<sup>\*</sup>This includes patients from Rongelap and Utrik combined at the beginning of fiscal year 1992.

Additionally, a radiologist began accompanying each mission, so that an immediate mammogram reading was available, greatly facilitating female patient care, as mammograms were accepted by virtually all of the women. Additionally, a gastroenterologist accompanied the missions on a regular basis for the primary purpose of performing routine flexible sigmoidoscopies; this physician was available for consultations. and after 1995. performed colonoscopies and upper endoscopies at U.S. Army Hospital on Kwajalein Island, thereby decreasing the need to refer patients off-island to Honolulu.

The total number of special procedures and mammographic tests completed for the entire duration of the Five-Year Report are listed in Table 2.

#### Specific medical conditions - thyroid nodules:

During the transition between vessel-based and land-based operations, one of the major emphases for the Marshall Islands Medical Program was to institute the detection of thyroid nodules by use of the ultrasound technique. The initial ultrasound equipment was supplemented by a 7.5 megahertz ultrasound machine from General Electric, which was used predominantly for the detection of thyroid nodules. At the end of the previous five-year report (which ended in 1991), there were several questions left unanswered regarding the thyroid nodules:

- -- will the entire mandated and volunteer comparison groups remained susceptible to new nodule formation?
- -- what is the role of gender in the development of thyroid nodules?
- -- what are the roles of radiation dosage and age in relation to the detection of nodules?
- was the nodule formation induced as a function of exposure to previous radiation?
- -- did the radiation increase the incidence of occult carcinomas?

Most of these questions were addressed in the previously-cited Cronkite paper. A summary of some of the important tables from that paper follows.

During the spring and fall 1994 surveys, thyroid ultrasounds were done on a total of 164 patients: 117 from the mandated group, and 47 from the volunteer comparison groups (Table 3). The total incidence of thyroid nodules detected in all of these groups was 25.0%. A total of 117 of these subjects (non-surgical patients) had not undergone any surgical procedures. Of these, 28.2% had developed thyroid nodules detectable by ultrasound.

The percentage of patients who had nodules greater than 10 mm. in diameter (the criteria for either an FNA or surgical exploration) was 10.4% for the total population of 164 patients, and 12.8% when the 117 non-surgical patients were taken into consideration. The number of patients who had nodules greater than 10 mm in diameter detected by ultrasound during the 1994 survey is depicted in Table 4.

All of these findings have been published in a recent publication, *Thyroid Disease Among the Rongelap and Utrik Population -- An Update* (Howard, etal., 1997). The initial thyroid ultrasound done in 1994 served as the basis for the majority of patients who came for annual visits.

In 1995 and 1996, an additional 230 ultrasounds were done on all patients from Rongelap, Utrik, and the comparison group. These are reported in Tables 5 and 6

During the 1995 and 1996 medical missions, a total of 240 ultrasounds were done on 113 patients. Of the 50 patients from the mandated group from Rongelap tested in 1995 and 1996, 22 subjects (or 44 percent) had detectable thyroid nodules on ultrasound. Of the 105 patients from the mandated group from Utrik testing in 1995 and 1996, 50 subjects (or 47 percent) had detectable thyroid nodules on ultrasound).

These numbers were similar between the two groups. In addition, 41 subjects (or 44 percent) of the comparison group also had nodules. Therefore, there does not appear to be any difference in detectable nodules between the mandated group and the volunteer comparison group. Of the subjects seen between 1995 and 1996, a total of 62 percent of the women were on thyroid suppression therapy. A total of 51 percent of

TABLE 2. Number of procedures done each year between 1992-1996.

Procedure	1992	1993	1994	1995	1996
X-rays	40	47	173	118	90
Mammograms	20	24	39	47	64
GI procedures		23	30	44	35

TABLE 3. Percentage of subjects in each patient group with thyroid nodules during the 1994 survey.

All Non Surgical Patients						,
	Total Patients	Patients with nodules*	Percent	Total Patients	Patients with nodules*	Percent
Rongelap	47	6	28.7	23	5	19.7
Utrik	70	23	42.7	55	17	47.0
Comparison	47	12	28.6	39	11	33.3
Total	164	42	25.0	117.	33.	28.2

<sup>\*</sup>Nodules detected only by ultrasound.

**TABLE 4.** Number of patients who had nodules greater than 10 mm in diameter, detected by ultrasound, during the 1994 survey.

	All Patients Numbers	Non Surgical Patients Number
Rongelap	3	2
Utrik	9	8
Comparison	5	5

**TABLE 5.** Total number of subjects with thyroid nodules detected on ultrasound in 1995 - 1996.

Gender	Mandated Group	Mandated Group	Comparison
	Rongelap	Utrik	Rongelap
Females	13	26	20
Males	9	24	21
TOTAL	22	50	41

TABLE 6. Total Number of ultrasounds performed on 113 patients which showed detectable nodules.

1995 1996

	Females	Males	Females	Males
Number	44	54	85	57
<10 mm	34	39	60	43
>10 mm	19	23	28	21
<10 & >10 mm	9	8	13	7
Mean # of nodules	1.68	1.44	1.59	1.47

the men were on thyroid suppression therapy. The thyroid stimulating hormone (TSH) levels in all of these patients between 1995 and 1996 were within normal limits. The availability of the ultrasound equipment also permitted FNA of the thyroid at the medical hospital base in Kwajalein. Table 7 lists all patients with nondiagnostic or suspicious FNAs that were referred for surveys. Initial success with thyroid FNAs was minimal while the program was still vessel-based on the Offshore Venture. Since the program was installed in the trailers on the Kwajalein Hospital site, greater usage of the thyroid ultrasound technique for biopsies occurred. As a result, fewer referrals were sent to Honolulu.

#### Histologic definitions:

Once the FNAs were completed, the specimens were sent back to New York for histologic diagnosis. If surgery was necessary, patients were referred to the contract tertiary care center, Straub Clinic and Hospital, in Honolulu. Histological classification occurred according to the pathology group at the Straub Clinic and Hospital.

The patients listed in Table 8 had surgery between 1992 and 1996. All of the surgical procedures were performed at the Straub Clinic and Hospital.

The thyroid ultrasound and pathology findings are summarized below:

The non-neoplastic adenomatous nodules were associated with higher doses of radiation, while neoplastic nodules developed in individuals who received lower doses of radiation. Women generally tended to have a larger number of palpable thyroid nodules than men. There were no significant differences between the thyroid nodules detected by ultrasound in the Rongelap and Utrik mandated communities, as compared to the volunteer group. Eight of the mandated patients were referred for surgical excision of the thyroid nodules, which were only detectable by ultrasound (proving the thyroid ultrasound to be a solid means of detecting small nonpalpable nodules). Of these patients, one had a hemorrhagic cyst, three had adenomatous goiters, two had follicular adenomas, one had adenomatous hyperplasia, and one had adenomatous hyperplasia with occult papillary carcinoma. The thyroglobulin levels in the patient who had occult papillary carcinaoma were

TABLE 7. FNAs Performed 1992-1996 (\* next to subject indicates patient is also included in Surgery table which is Table 8). All nondiagnostic or suspicious FNAs were referred for surgery.

Subject	Date of FNA	Island Group
No. 1	1996	Mandated
No. 2	1995	Mandated
No. 3*	1995	Mandated
No. 4	1996	Mandated
No. 5	1995	Mandated
No. 6	1994	Mandated
No. 7*	1994	Mandated
No. 8	1996 (twice)	Mandated
No. 9	1996	Comparison
No. 10	1995 & 1996	Comparison
No. 11	1996	Comparison
No. 12	1996	Comparison
No. 13	1994	Comparison
No. 14	1994 & 1995	Comparison
No. 15	1994	Comparison
No. 16	1994	Comparison
No. 17	1995	Comparison
No. 18	1995 & twice in 1996	Comparison
No. 19*	1994, 1995, & 1996	Mandated
No. 20	1996	Mandated
No. 21	1996 (twice)	Mandated
No. 22	1996	Mandated
No. 23	1996 (twice)	Mandated
No. 24*	1994 (twice)	Mandated
No. 25	1994	Mandated
No. 26	1994 & 1996	Mandated
No. 27*	1994	Mandated

TABLE 7 (continued). FNAs Performed 1992-1996 (\* next to subject indicates patient is also included in Surgery table which is Table 8). All nondiagnostic or suspicious FNAs were referred for surgery.

Subject	Date of FNA	Island Group
No. 28*	1994	Mandated
No. 29*	By Japanese	Mandated
No. 30	1994	Mandated
No. 31	1995 & 1996	Mandated
No. 32	1994 & 1995	Mandated
No. 33	1995	Comparison
No. 34	1994	Comparison

TABLE 8. Thyroid Surgery Patients 1992-1996.

Subject	Date of Surgery	Histopathologic Diagnosis	Island Group
No. 1	1994	Follicular Adenoma	Mandated
No. 2	1996	Adenomatous Hyperplasia	Mandated
No. 3	1994	Atypical Follicular Cells, No Thyroid Tissue	Mandated
No. 4	1996	Adenomatous Goiter	Mandated
No. 5	1994	Adenomatous Goiter	Mandated
No. 6	1994	Adenomatous Goiter	Mandated
No. 7	1995	Adenomatous Hyperplasia and Occult Papillary Carcinoma	Mandated
No. 8	1995	Follicular Adenoma, Focal Benign Hyalinized Nodule, Focal Benign Adenomatous Hyperplasia	Mandated

within normal limits. An interesting finding was that thyroid suppression had been initiated in the Rongelap group earlier in the course of the Marshall Islands Medical Program. Interestingly, the patients in the Rongelap mandated group had a lower incidence of ultrasound detectable thyroid nodules, as compared to the Utrik group. Also of interest was the fact that of the five patients who had thyroid tissue at surgery, four were from Utrik and only one from Rongelap. It is noteworthy that thyroid suppression does appear to have either reduced the incidence of thyroid cancers due to continued suppression of the

TSH, or reduced the incidence of new thyroid cancers in the remnant thyroid tissue. The higher percentage of nodules detected between 1995 and 1996 is a reflection of the increased number of patients that were followed up during these two years. An incidence of approximately 28% in the group that had been studied up to 1994 was previously reported.

In either event, patients from Utrik did not have or need many surgical procedures, and had not been previously suppressed with thyroid hormone replacement. Therefore, the findings of a higher incidence of thyroid surgery in this group may simply be a reflection of the slow, but benign, process of nodule formation, which appears to be inevitable in virtually all endocrine tissues.

Several studies have shown that the addition of L-thyroxine to patients who are being treated for benign solitary cold nodules is effective in suppressing the growth of the nodules (LaRosa et al., 1995). It should be noted that none of the thyroid nodules that were detected by ultrasound in the group were palpable. Numerous studies have shown that clinical palpation of the thyroid is less sensitive than thyroid ultrasonography when identifying nodules. The detection limit for most thyroid examinations is a minimum of 1.5 cm in diameter (Tan et al., 1995).

Several long-term studies have been conducted in patients who have previously undergone thyroid surgery and radioactive iodine ablation for papillary thyroid carcinoma. In a long-term study of over 35 years, cumulative recurrence rates of thyroid cancers were less than 9% (Mazzaferri and Jhiang, 1994).

The second major emphasis for this report was to follow up on mammograms in women, both in the mandated and volunteer comparison groups. No mammography was performed in 1994 because it was agreed that the vessel-based unit was not up to current standards. In 1995, arrangements were made with the U.S. Army Hospital on Kwajalein Island to refer all female patients for routine mammography. In 1995, patients requiring diagnostic mammography were referred to the Straub Clinic and Hospital. In 1996, with the inception of the land-based program and the availability of a radiologist, diagnostic mammography was performed at the U.S. Army Hospital on Kwajalein Island. During the course of the five years, palpable nodules were detected on a number of patients. Initially, the majority of these patients were referred off-site to Honolulu for diagnostic biopsies and surgical procedures. These patients were subsequently followed-up through the Straub Clinic and Hospital. In 1996, arrangements were made with the Kwajalein surgical staff to perform routine biopsy procedures, thus creating a reduction in the number of Honolulu referrals. There were a total of 39 referrals made for mammogramrelated abnormalities. These patients were referred for surgical procedures or evaluations at Kwajalein or Honolulu. A number of these procedures turned out to be benign, and only one patient was detected to have breast cancer. This patient was treated with radiation therapy in Honolulu, since that was her location of residence.

The third major initiative for this report was to institute the blood tests for PSA for all males who had palpable prostate enlargements. This resulted in

approximately eight patients with detectable levels of PSA, who required referrals to the urology services in Honolulu.

#### Sigmoidoscopies and GI workup:

Sigmoidoscopies were done on the Offshore Venture and at the U.S. Army Hospital on Kwajalein Island. Once the program became land-based, two additional Olympus flexible sigmoidoscopy units were purchased for the medical program. This increased the efficiency of the gastroenterologist's time. Also, it should be noted that both units were in compliance with the increasingly stringent sterilization requirements. The sigmoidoscopies, colonoscopies and proctoscopic examinations were conducted either by the visiting gastroenterologist, or by one of the surgeons located permanently on Kwajalein.

Hepatitis B surface antigen was detectable in a number of patients, who were routinely monitored with alphafetoprotein for the development of any hepatocellular problems. This was an ongoing procedure, and patients were treated annually with alphafetoprotein levels, hepatic ultrasound, and liver biopsies, as indicated.

Hematological evaluations were continued when appropriate by means of routine blood counts, platelet counts, serum protein electrophoresis, and bone marrow aspirations. The results of the CBC's and chemistries are listed in Appendix B.

## Referrals to the Tertiary Medical Care Center and to the RMI Government:

As previously indicated, the number of referrals to the Tertiary Medical Care Center in Honolulu decreased after the program became land-based. The overall referrals for various patients are listed in Table 9. In general, the thyroid-related referrals were mainly to repeat thyroid FNAs, to perform surgical excision of thyroid nodules, and to follow up with radioactive iodine scans for those patients who had previous thyroid cancers.

#### Patient Deaths During 1992 - 1996:

There were a total of 25 of the original 253 mandated patients and 14 of the 227 volunteer comparison patients who expired during this reporting period. The total percentage of mandated patients who expired during this reporting period was 9.99%; the expiration percentage of the volunteer comparison patients who returned for annual visits was 6.2%. After 42 years, there still continue to be few differences

TABLE 9. Referrals to the Tertiary Care Center and to the RMI Government.

Diseases/Conditions	No. of Subjects	% of Total
Anemia	26	7
Back pain	1	<1
Breast	39	11
Cardiology	3	1
Dental	2	1
Diabetes	13	4
Endocrine visits	10	3
Gastroenterology	73	21
Gynecology	30	9
Hypertension	10	3
Leg cramps	1	<1
Non-thyroid neck mass	3	1
Neurological	2	1
Ophthalmological	12	3
Osteoarthritis	2	1
Pituitary tumor	1	<1
Pulmonary	18	5
Skin lesions	1	<1
Surgery (non-thyroid)	5	1
Thyroid	70	20
Urology	26	7
Total referrals	348	100%

between the percentage of patients in the mandated groups compared to the gender and age-matched volunteer patients. It should be noted that because many patients lived on atolls or outer islands located a great distance from major population centers, the cause of death is usually not recorded and, therefore, unknown. Individual summaries for each of the patients who expired within each group (mandated and volunteer comparison) are shown below:

Deceased patients in the mandated groups are specified by island: Rongelap (R) and Utrik (U).

Subject No. 1 (R). This was an 82-year old woman whose main symptoms were inability to walk, B12 deficiency, and probably mild myelodysplastic syndrome. She also had persistent psoriasis and hypothyroidism. She was being treated with Synthroid 200 mcg daily and B12 injections for the anemia. The cause of death is unknown.

Subject No. 2 (R). This patient was a 60-year old male who had status post thyroidectomy and laryngectomy for squamous cell carcinoma. His laryngeal carcinoma developed in 1992, when he first had symptoms of progressive hoarseness for approximately 8 months. The diagnosis was made by laryngoscopy and the findings were of multiple nodules among the vocal chords. He also received chemotherapy for metastatic laryngeal carcinoma to the right upper lobe of the lung. His thyroidectomy was in 1977 for a benign disease. He had a history of hypothyroidism for which he was being treated with Synthroid 200 mcg daily. The cause of death was not reported, but may have been due to metastatic laryngeal carcinoma to the right upper lobe of the lung.

Subject No. 3 (R). This was an 82-year old male who was last seen in 1992 complaining of mild back pain which was due to an injury. His physical examination was unremarkable at that time, and his only problems were the presence of bilateral cataracts and stable anemia. He also had very mild renal insufficiency as evidence of a slight increase in serum creatinine. The patient was also known to have hereditary neuropathy. The cause of his death is unknown.

Subject No. 4 (R). This was a 60-year old male who was seen in March 1996. He had a history of blood in his stools for which he was being examined by colonoscopy. This test found no evidence of malignancy, and no identifiable lesions were visible. The patient had mild renal insufficiency as evidence of slight increase in serum creatinine and B12 deficiency. He was also noted to have an abnormal PSA. He was also being treated with Vasotec for mild hypertension. The immediate cause of his death is unknown.

Subject No. 5 (R). This was a 64-year old male who was last seen in March 1994, and his history included hypothyroidism for which he received Synthroid 200 mcg daily. His past medical history included a mild degree of renal impairment, and minimal upper GI reflux treated intermittently with Maalox. He was also known to have Hansen's disease with extensive multiple amputations of his fingers and toes. He also had below knee amputation of the right leg also due to Hansen's disease. The cause of his death is unknown.

Subject No. 6 (U). This was a 78-year old female who was last seen in 1995 as a home visit. She had

a long standing history of diabetes mellitus and was treated with Micronase 5 mg daily. She was also receiving 100 mcg of Synthroid daily for a prior history of thyroidectomy for benign disease. When she was last seen at home, she was confined to bed and had a low blood pressure, but the rest of the physical exam was unremarkable. The immediate cause of death is unknown.

Subject No. 7 (R). This was a 78-year old male who was last seen in 1992 and expired in 1995. He declined visits to the medical facilities when he was contacted during the missions. When he was last seen, he had a history of decreasing vision and difficulty walking. He had a fixed flexion deformity of his knee and diminished flexion of the spine. He also had hypothyroidism for which he was receiving 200 mcg of Synthroid daily. In 1991, he had been seen at Straub Clinic and Hospital for tuberculosis. He also had a history of cerebral vascular accident with left-sided hemiparesis. The cause of his death is unknown.

Subject No. 8 (U). This was an 80-year old male who was last seen in 1991. The patient had a history of left-sided hemiparesis and infection of his right foot. He had a previous history of left lower extremity below knee amputation. He also had a history of peripheral neuropathy and mild cataracts. The immediate cause of his death was not reported.

Subject No. 9 (U). This was a 92-year old male who expired in Majuro in 1993, due to pneumonia and senility. He was last seen by the medical program in 1992 in a home visit. At that time, his predominant complaints were mild dermatitis, constipation and a pilonidal cyst. He was also found to have benign prostatic hypertrophy. He was given symptomatic treatment at that time with local creams for his skin lesions and Dulcolax for his constipation. He was admitted to Majuro Hospital for a total of five days and expired in the hospital.

Subject No. 10 (U). This was an 89-year old male who had a history of iron deficiency anemia and guaiac positive stool. He was last seen as a referral to Straub Clinic and Hospital for a workup of a large scrotal mass, and low hemoglobin and hematocrit. The patient had surgery for left inguinal hemial repair and left-sided orchiectomy. The pathology report of this specimen indicated that the patient had a Leydig cell tumor with evidence of pulmonary metastases as seen on chest x-ray. The cause of his death was not reported, but may have been due to the metastatic Leydig cell tumor.

Subject No. 11 (U). This was a 45-year old female who was seen by the medical program in March 1993. She had a history of long standing and poorly controlled diabetes mellitus. In May 1990, she had a left breast mass which was found to be benign. This patient was admitted to Majuro Hospital in August 1993, and the immediate cause of her death was reported to be cardiac arrest which was presumed to be due to electrolyte imbalance secondary to chronic diarrhea.

Subject No. 12 (U). This was an 82-year old male who was last seen as a home visit in 1995. The patient expired in March 1996. He had a history of diabetes mellitus with acceptable control, and chronic anemia which was stable. He also had status post right toe amputations due to his diabetes. His diabetes was adequately controlled with Micronase 10 mg daily. His prior history included surgery for benign prostatic hypertrophy in 1980, and surgery for cataracts in 1987 and 1990. The immediate cause of his death is unknown.

Subject No. 13 (U). This was a 40-year old male who was last seen in 1992. The patient had a history of hypertension for which he was being treated with Vasotec 10 mg daily. The patient also had an elevated prolactin level which was not related to hypothyroidism or the result of other medications that he was receiving. Work up of his pituitary gland included a CT scan which showed an empty sella associated with elevated levels of prolactin. The high levels of prolactin also caused him to be impotent. The patient also had probable coronary artery disease with cardiomyopathy, and there was evidence of myocardial infarction on an old cardiogram. The patient as a chronic smoker and also had been a heavy alcohol drinker, which may have contributed to the cardiomyopathy. The immediate cause of his death is unknown.

Subject No. 14 (U). This was a 71-year old woman who was last seen at the medical mission in March 1993. She was referred to Straub Clinic and Hospital in May 1991 for a questionable abdominal mass. Work up at that time was unremarkable for any masses. She was seen again in 1992. There was a concern of weight loss. She was seen once more in April 1993 for recurrent abdominal problems. A mass was discovered by CT in the region of the aorta and a biopsy of this mass indicated poorly differentiated adenocarcinoma, with an unknown primary source. The cause of death is unknown, but may have been due to the poorly differentiated adenocarcinoma.

Subject No. 15 (U). This was a 90-year old woman who was last seen in the medical program in April 1992. She had a history of constipation, hematuria, normocytic anemia and borderline hypertension. The patient also had bilateral cataracts and nonspecific complaints of joint pains and was taking symptomatic treatment for all of these problems. The cause of her death was not immediately apparent.

Subject No. 16 (U). This was a 67-year old male who was last seen for a visit in March 1992. He had a history of myocardial infarction, hypertension, and diabetes mellitus, and was being treated with Micronase 5 mg daily and Vasotec 5 mg daily. His diabetes was inadequately controlled and he had multiple ulcerations over his extremities. During his last visit he was found to have a prominent abdominal aorta and was being referred to Majuro for an ultrasound. The immediate cause of his death is unknown.

Subject No. 17 (U). This was a 75-year old woman who had been seen in March 1992 by the medical team. She was found to have out-of-control diabetes, increasing kidney function impairment and hypertension. In 1991, she was referred to Honolulu for persistent microscopic hematuria, which was found to be due to a renal calculus. A mammogram showed nipple retraction, and there were vascular calcifications in both breasts. The cause of her death is unknown.

Subject No. 18 (U). This was an 83-year old female who was last seen during the spring 1993 mission. Her past history included colon cancer surgically corrected in 1985. She had negative colonoscopies in 1988. She was found to be unresponsive and to have massive urinary tract infection. She was treated with intravenous antibiotics and hydration, and then transferred to Majuro Hospital for continued care. The immediate cause of her death was unknown but presumed to be due to urosepsis and coma.

Subject No. 19 (R). This was a 78-year old male last seen in the fall of 1993 with a history of diabetes with ophthalmopathy. He also had a history of hypertension, hypertriglyceridemia, and positive Hepatitis B. The patient expired in 1994; immediate cause of death is unknown.

Subject No. 20 (R). This 89-year old male was last seen in August 1994 at the Straub Clinic and Hospital He had colonic polyps, an abnormal thyroid ultrasound, a history of anemia, and hypothyroidism replacement with Synthroid. In April 1994, he also

had a history of a CVA and aphasia. The patient expired in October 1994; the cause of his death is not known.

Subject No. 21 (R). This 75-year old female was last seen in 1994 during the fall mission. She had been taking Synthroid for hypothyroidism. She also had a history of Type II Diabetes Mellitus which was treated with Micronase. She was status post cerebral vascular accident. The patient expired in July 1995, and the immediate cause of her death is not known.

Subject No. 22 (U). This patient was an 83-year old male, last seen during the fall 1993 mission. He had a history of anemia, glaucoma, mild hypertension, and renal abnormalities. His past history also included aortic stenosis and hypertriglyceridemia. The immediate cause of his death is not known.

Subject No. 23 (U). This 77-year old male patient had a history of chronic obstructive lung disease and hematuria, and had been seen at the Straub Clinic and Hospital for abdominal aortic aneurysm. He had a urinary cytology which showed no evidence of carcinoma. He was extensively worked upon with abdominal CT and renal ultrasound at the Straub Clinic and Hospital, and the only abnormality detected was a large aneurysm. No cause of death was identifiable.

Subject No. 24 (U). This female was born in 1923 and probably died in 1992. The patient was a 69 year old female who had a history of iron deficiency anemia, dementia, organic brain syndrome, and hypothyroidism. The patient was homebound, and had been in that condition for several home visits, the last one in 1992. The immediate cause of her death is unknown.

Subject No. 25 (U). This 62-year old female was an unknown diabetic for many years with a history of back and knee pain, as well as hemorrhoids. Her diabetes had been well controlled, and the patient's pain symptoms were relieved with analgesic therapy. The patient was last seen in September 1993, and the immediate cause of her death is unapparent.

Comparison group (All volunteer comparison patients were from Rongelap):

Subject No. 1. This was a 56-year female last seen during the spring 1996 mission. She had a history of congestive heart failure, atrial fibrillation,

microhematuria, and diabetes mellitus. The patient had aortic stenosis and regurgitation with angina, and had required cardiac surgery for valvular replacement in 1980. The problem with the congestive heart failure appeared to be worsening when she was seen during the mission. An electrocardiogram showed atrial fibrillation, and the chest x-ray showed congestive cardiomegaly with pleural effusions bilaterally. The patient was treated during the mission, and then referred to the RMI Government for continued care. The immediate cause of her death was unknown.

Subject No. 2. This was an 84-year old female who was seen during the spring 1993 mission. She had a history of anemia of non-specific origin, a heart murmur and elevated cholesterol levels. She also had a history of diabetes mellitus and mild renal impairment. She was treated with Micronase 5 mg daily, and symptomatic treatment for analgesia with Tylenol. The immediate cause of her death was unknown.

Subject No. 3. This was a 62-year old woman with a previous history of anemia and nonspecific joint pains, as well as diabetes mellitus with adequate control. She had been treated with Micronase (4 tablets twice a day) and multivitamins. She had no abnormalities noted on her most recent thyroid ultrasound. Flexible sigmoidoscopy done during that visit was normal. There was no immediate known cause of death noted.

Subject No. 4. This was an 81-year old woman with a history of diabetes mellitus and status post thyroid carcinoma treated surgically in 1982. It was an occult papillary carcinoma. She had been treated with Micronase 5 mg daily and Synthroid 100 mcg daily. She also was known to have nonspecific joint pains and a history of anemia. She was last seen in March 1996, and treated with the above mentioned medications. She also had elevated creatinine, and high triglycerides and cholesterol. The immediate cause of death is not known. She is known to have expired in September 1996.

Subject No. 5. This was a 70-year old male who had a previous history of hypothyroidism diagnosed in 1992. He was being treated with Synthroid 200 mcg daily. Routine thyroid ultrasound indicated a multinodular gland with some retrosternal extension. FNA was done on one of the nodules, and this was nondiagnostic. The patient also had a history of cataracts in both eyes, and had a routine sigmoidoscopy in 1992 which was normal. The immediate cause of his death is not known.

Subject No. 6. This was a 73-year old female who was last seen during the spring 1985 mission. No other records were available after 1985 to make a satisfactory assessment of her medical condition. She was, however, known to be hypertensive, and was treated with Hydrochlorthizine. There is no known cause of death.

Subject No. 7. This was a 47-year old woman who was last seen during the fall 1995 medical mission. She had a history of diabetes mellitus treated with Micronase. She also had a history of fungal infections and microhematuria. Her thyroid function tests were normal and her last known blood tests for serum chemistries were normal. She also had iron deficiency anemia, a urinary tract infection, and multiple joint pains. The immediate cause of her death is not known.

Subject No. 8. This was an 82-year old male who was last seen during the fall 1993 mission. He had progressive anemia and refused to have bone marrow testing. A house call was made to evaluate his medical status. He was found to be unresponsive during his visit but moved all his extremities. He had some cough and fever for about a month prior to the home visit. The impression was that of severe cachexia secondary to his age, and the family decided against transporting the patient for further care at a hospital. The patient reportedly died soon after the home visit.

Subject No. 9. This was a 62-year old female who was last seen during the Medical mission in March 1993. She had a history of diabetes mellitus which was treated with Micronase 5 mg daily. She also had nonspecific joint pains, as well as vulvulitis. Her laboratory tests during the last visit indicated no specific abnormalities. She was later admitted to Majuro Hospital in a coma of 24-hour duration and sepsis. She was eventually diagnosed with meningitis which was reported to be the cause of her death on the death certificate.

Subject No. 10. This was a 70-year old male seen at Ebeye Hospital during the spring 1994 mission. He had been admitted to Ebeye Hospital with a history of osteomyelitis, and sepsis. He also was a known diabetic and was being treated with Micronase 5 mg daily. He had a prior history of thrombocytopenia of unknown etiology. During the hospital visit he was given Ciprofloxin 500 mg twice a day and was given a renewal of his Micronase prescription. The immediate cause of his death was

not known but presumed to be sepsis due to osteomyelitis.

Subject No. 11. This was a 53-year old male who was last seen during the 1994 fall mission. He expired in 1995. He had a history of cerebral vascular accident which occurred several years ago, and he had residual left-sided hemiparesis. He had impaired renal function, and a history of anemia. He also had a history of hypertension, which was controlled with Nifedipine 10 mg four times daily. The patient had no thyroid abnormalities. The immediate cause of his death was not known.

Subject No. 12. This was a 70-year old male who was last seen during the fall 1995 mission. The patient had a history of multiple thyroid nodules which were diagnosed on thyroid ultrasound. These were benign. He also had a history of hypertension, bronchial asthma with chronic obstructive lung disease, and congestive cardiac failure. He also had Type II Diabetes Mellitus associated with obesity. The patient expired in 1996 and the immediate cause of his death was not known.

Subject No. 13. This was a 51-year old female last seen during the fall 1993 mission. She had a history of urinary tract infection, Diabetes Mellitus with neuropathy, degenerative arthritis of the cervical spine, and a class III PAP smear. She had a painless mass in the right breast which was most likely of inflammatory origin. She was referred to the 177 Health Care Program for treatment and excision of the mass. The immediate cause of her death was unknown. She expired in 1996; since 1994, she had not been attending follow-up visits to the Medical Program.

Subject No. 14. This was a 71-year old female last seen during the fall 1992 mission during a home visit. During the last mission that she was seen, she was found to have Type II Diabetes Mellitus (she took insulin for a short time, then switched to oral agents), hypertension, hearing difficulty, and bilateral cataracts. She was treated with Micronase 5 mg daily and Vasotec 10 mg daily. She subsequently refused other visits and expired in 1995. The immediate cause of her death is unknown.

#### **BIBLIOGRAPHY**

Cronkite, E.P., Bond, V.P., Conard, R.A., Shulman, N.R., Farr, R.S., Cohn, S.H., Dunham, C.L., and Browning, L.E. 1955. Response of human beings accidentally exposed to significant fallout radiation. J. Amer. Med. Assoc. 159:430-434.

Lessard, E., Miltenberger, R., Conard, R., Musolino, S., Naidu, J., Moorthy, A., and Schopher, C. 1985. Thyroid-absorbed Dose for People at Rongelap, Utrik and Sifo on March 1, 1954. BNL 51882.

Conard, R.A., Meyer, L.M., Rall, J.E., Lowery, A., Bach, S.A., Cannon, B., Carter, E.L., Eicher, M., and Hechter, H. 1958. *March 1957 Medical Survey of Rongelap and Utrik People Three Years after Exposure to Radioactive Fallout.* BNL 501 (T-119).

Howard, J.E., Vaswani, A.N., and Heotis, P.1997. Thyroid Disease Among the Rongelap and Utrik Population — An Update. Health Phys. 73(1):190-198.

LaRosa, E.L., Ludo, L., Giuffrida, D., Gullo, D., Vigneri, R., and Belfiore, A. 1995. Levothyroxine and potassium iodide are both effective in treating benign solitary solid cold nodules of the thyroid. Ann. Intern. Med. 122:1-8.

Tan, G.H., Gharib, H., and Reading, C.C. 1995. Solitary thyroid nodule. Arch. Intern. Med. 155:2418-2423.

Mazzaferri, E.I. and Jhiang, S.M. 1994. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am. J. Med. 97:418.

#### **Epilogue**

by E.P. Cronkite, M.D.

On March 1, 1954 following a detonation of a thermonuclear bomb, Rongalap and Utrik inhabitants, as well as American Servicemen were exposed to fallout. Several Marshallese had sufficient fallout material on their skins to produce Beta burns. The burns healed leaving scars in some individuals. There were significant decreases in white blood cell and platelet counts which ultimately returned to normal. There had been nausea, vomiting and diarrhea in some of the Marshallese which was not reported in the exposed Americans. The team that observed the exposed persons returned to the US when it became evident that the exposed persons were recovering from the effects of the fallout radiation.

On July 12-13 1954, Dr. John Bugher, Director, Division of Biology and Medicine of Atomic Energy Commission convened a meeting of all personnel that had observed the Rongalap and Utrik inhabitants caught in radiation fallout in order to discuss the future management of these Marshallese patients. He made it clear that the DBM-AEC would be responsible for the future observation and care of the Marshallese that had been exposed on Ailinginae, Rongerik and Utrik Atolls and that the Department of the Interior was responsible for general medical surveillance of the Marshallese on other atolls. It was decided that V.P. Bond would lead a team to survey the status of the Rongalap and Utrik inhabitants of the above atolls six months after the accident and that E.P. Cronkite lead a team 12 months after the accident. Dr. R.A. Conard assumed responsibility in 1956, for direction of the continuing Marshallese Medical Program involving those individuals exposed on Ailinginae, Sifo, Rongelap and Utrik under auspices of BNL. For 25 years, Dr. Conard guided the program with skill and diplomacy. There were some turbulent times, when through misunderstanding of the role of the BNL team, the Marshallese became uncooperative largely as a result of political problems.

There is no question that the radiation was responsible for skin burns, epilation, temporary suppression of hemopoiesis, thyroid hypofunction, thyroid tumors and probably responsible for the fatal case of acute leukemia. One can never be absolutely certain since it is not possible to tell the difference between spontaneous leukemia and radiation-induced leukemia. Based upon the extensive data collected in Japan on the survivors from the atomic bombs at Hiroshima and Nagasaki, it is most unlikely that further radiation effects will be observed in the Rongalap and Utrik inhabitants caught in radioactive fallout. However, there are problems traceable to the nuclear bomb testing in the Marshall Islands.

# Appendix A

#### APPENDIX A

# PROFESSIONAL STAFF PARTICIPATING IN THE 1992-1996 MARSHALL ISLANDS SURVEYS

NAME/SPECIALTY	PARTICIPATING SURVEY	AFFILIATION
CARDIOLOGY		
Maj Janet Hays, MD	S/92	Senior Cardiology Fellow Brook AMC San Antonio, TX
DERMATOLOGY		
Richard Ostreicher, MD	S/92	Sr Resident, Dermatology NY Univ Med Center NYC, NY
EMERGENCY MEDICINE		
Douglas Binder, MD	F/93	Resident, Emergency Med Bronx Municipal Hosp Ctr NYC, NY
Eric Lindborg, MD	F/95, S/96	Chief of Staff Kwajalein Hospital Kwajalein, MH
Steven Mehaffey, MD	S/95	Staff Physician Kwajalein Hospital Kwajalein, MH
ENDOCRINE		
LaVonne Berg. MD	S/92	Fellow, Endocrinology Case Western Reserve Univ Cleveland, OH
Robert Blank, MD	S/95	Fellow, Endocrinology Rockefeller Univ NYC, NY
Col Michael Bornemann, MD	S/94	Chief, Endocrinology Dept of Medicine Tripler AMC Honolulu, HI

Barbara Fleming, MD	S/93	Assoc Chief of Staff VA Medical Center Cleveland, OH
CPT Lloyd Hancock, MD	S/96	Asst Chief, Endocrinology Eisenhower Army Med Ctr Fort Gordon, GA
Maj Gregory Hughes, MD	S/94	Staff Endocrinologist Tripler AMC Honolulu, HI
Mark Lakshmanan, MD	S/93	Senior Instructor Dept of Endocrinology Metro Health Med Ctr Cleveland, OH
James Magner, MD	F/96	Professor of Medicine East Carolina Univ Sch of Med Greenville, NC
Lawrence Parker, MD	F/94	Asst Chief, Endocrinology VA Med Ctr Long Beach, CA
Maj R. Michael Tuttle, MD	F/93, F/96	Chief Endocrinology Walter Reed AMC Washington, DC
Ashok Vaswani, MD	S/92/ F/94, F/95, S/96	Consulting Endocrinologist, MIMP Asst Prof of Medicine, SUNY, NY
CMD Ann Yoshihashi, MD	S/95	Fellow, Endocrinology National Naval Med Center Bethesda, MD
FAMILY PRACTICE		
CDR Nathaniel Cobb, MD	F/96	Director, Indian Health Service, PHS Albuquerque, NM
Kevin Cook, MD, MPH	F/92	Staff Physician Kwajalein Hospital Kwajalein, MH

**GASTRONENTEROLOGY** 

Michael Bliss, MD S/92, F/95 Prof of Medicine

Boston City Hospital

Boston, MA

Peter Ells, MD S/96 Acting Dir, Gastroenterology

SUNY, Stony Brook Stony Brook, NY

Wayne Lucas, MD F/96 Fellow, Gastroenterology

Boston City Hospital

Boston, MA

**HEMATOLOGY** 

William Adams, MD S/92, F/92 Medical Dir, MIMP (to 1992)

Brookhaven National Lab,

Upton, NY

Jean Howard, MD S/92, F/92, S/93, F/93, Hematology/Oncology

S/94, F/94, S/95, F/95, Medical Dir, MIMP (from 1993) Brookhaven National

Lab, Upton, NY

**INFECTIOUS DISEASES** 

Dina Toren, MD F/92 Dept of Infectious Disease

Fellow, NY Univ Med Center

NYC, NY

**INTERNAL MEDICINE** 

Colin Atterbury, MD S/93 Chief of Staff

Yale School of Med

New Haven, CT

Maj Benjamin Berg, MD S/94 Staff Pulmonologist

Dept of Medicine

Tripler AMC, Honolulu, HI

Michael Hamilton, MD, MPH F/94 Clinical Asst Prof of Medicine

Duke Univ Med Ctr

Durham, NC

Thomas Minor, MD S/95 Fellow, Medicine

Mayo Clinic Rochester, MN **NEPHROLOGY** 

Staff Nephrologist S/92 James Barr, MD, PhD Dept of Medicine **Brook AMC** Houston, TX

**NUCLEAR MEDICINE** 

Prof Emeritus, Nuc Med F/95 John Harbert, MD

Georgetown University McLean, VA

Advisor to Presidential Committee on Radiation

Henry Royal, MD S/96 Prof of Radiology

Mallinckrot Inst St. Louis, MO

Member of Presidential Committee on Radiation

OB/GYN

F/95 Private Practice, GYN Stuart Abrahams, MD

Greensboro, NC

Fellow/Instructor, GYN Frank Anderson, MD, MPH F/93

John Hopkins Univ Baltimore, MD

Pediatric Gynecologist S/93, S/94, S/95 Lauren Brown, MD

Children's Hospital

Boston, MA

S/94 Chief Resident, GYN Pui Chun Cheng, MD

Stony Brook Univ SUNY, Stony Brook, NY

Private Practice, GYN Richard Gallagher, MD F/96

Concord, MA

Staff Physician, GYN F/94 Col Samuel Heth, MD

Tripler Army Med Ctr

Honolulu, HI

Robert Holland, MD F/95 Staff Physician, GYN

Mountainview Woman's

Health

Grandview, WA

F/96 Private Practice, GYN William Inkret, MD

Denver, CO

Michael Janicek, MD	S/93	Chief Resident, GYN John Hopkins University Baltimore, MD
CMD Robert Laliberte, MD	S/96	Chairman, Dept of OB/GYN Phoenix Indian Med Center Phoenix, AZ
Gilda Lorensen, MD	F/94	Staff Physician, GYN Carolina Permanente Med Grp Raleigh, NC
Rochelle Mathieu, RN, NP	F/93	Private Practice, GYN Hilo, HI
Leonard Schonberg, MD	S/96 :	Private Practice, GYN Helena, MT
John Tucker, MD	S/92	Asst Clinical Prof of GYN Harlem Hospital NYC, NY
Marina Torbey, MD	S/92	Attending Physician, GYN Albert Einstein College of Medicine Bronx, NY
Maj Mary Zozulin, MD	S/95	Staff Physician, GYN US Air Force MC Grand Forks, ND
PATHOLOGY		
Donald Paglia, MD	S/93, S/94	Prof of Pathology UCLA Los Angeles, CA
PULMONARY		
Herman M. Blaton, MD	S/92	Chief, Pulmonary Service Brooke AMC San Antonio, TX
Robert Fallat, MD	F/93	Dir of Pulmonary Research California Pacific Med Ctr San Francisco, CA
Maj Joseph Kern, MD	F/94	Staff Physician, Pulmonary Div Madigan Army Center, Tacoma, WA

CDR Scott Sageman, MD	F/96	Staff Physician, Pulmonary Div Naval Med Ctr San Diego, CA
RADIOLOGY		
William Brant, MD	F/94	Assoc Prof of Radiology Univ of CA - Davis Davis, CA
Maj Allen Chantelois, MD	S/92	Staff radiologist Fitzsimmons AMC Aurora, CA
LCDR Daniel Davis, MD	F/96	Diagnostic Radiologist Dept of Radiology National Naval MC Chesapeake, VA
CPT Michael Freckleton, MD	S/95	Chief, Outpatient Radiology Air Force MC Lackland, TX
CPT Walter Goff II, DO	F/94	Chairman, Radiology Dept Naval MC San Diego San Diego, CA
Col Chris Jennings, MD	S/96	Staff Radiologist Tripler Army Med Center Honolulu, HI
CMD David Lawrence, MD	S/94	Director, MRI National Naval Med Ctr Bethesda, MD
LTCD Robert McFarland, MD	S/96	Staff Radiologist San Diego Naval Med Center San Diego, CA
Maj David May, MD	S/95	Staff Radiologist Wilford Hall AFB Lackland, CA
Philip Moyers, MD	F/95	Fellow, Radiology & Nuc Med Barnes Hospital St. Louis, MO
Robert Shepherd, MD	F/95	Chair of Radiology Univ of Texas Health Center Tyler, TX

Virginia Toombs, MD	F/96	Private Practice, Radiology Palo Alto California
Philip Wiest, MD	F/94	Asst Prof Radiology VA Medical Ctr Albuquerque, NM
SURGEON		
Earl Thornhill, MD		Staff Physician Kwajalein Hospital Kwajalein, MH
NURSES		
Altina Anien	F/93, F/96	Majuro Hospital Majuro, MH
Toltha Arelong	F/92	Majuro Hospital Majuro, MH
Sandy Balos	F/95	Majuro Hospital Majuro, MH
Marlene Brady	F/94	Kwajalein Hospital Kwajalein, MH
Kathy Campbell	S/92, F/92	Kwajalein Hospital Kwajalein, MH
Trudy Campbell	S/93	Kwajalein Hospital Kwajalein, MH
Lynda Firment	S/94	DOE Washington, DC
Deborah Greenhill	S/94	Kwajalein Hospital Kwajalein, MH
Reine Heine	S/96	Majuro Hospital Majuro, MH
Aurelia Inkret	F/96	Private Practice Denver, Co
Stanley Jacob	S/95	Ebeye Hospital Ebeye, MH
Helen Jetnil	F/94	Majuro Hospital Majuro, MH
Nennet Joel	S/95	Majuro Hospital Majuro, MH

Kelly Johnson	S/95	Tripler AMC Honolulu, HI
Leslie Kirkham	F/95	Kwajalein Hospital Kwajalein, MH
Clementina Lalimo	F/96	Majuro Hospital Majuro, MH
Tinar Lalimo	S/93	Majuro Hospital Majuro, MH
Rosebeth Lang	S/96	Majuro Hospital Majuro, MH
Risen Lomae	F/94	Majuro Hospital Majuro, MH
Utena Marshall	F/9, S/95	Majuro Hospital Majuro, MH
Tina Naisher	F/95	Majuro Hospital Majuro, MH
No Phillips	S/93	Majuro Hospital Majuro, MH
Linda Puchon	F/93	Kwajalein Hospital Kwajalein, MH
Nanik Rantak	S/93	Majuro Hospital Majuro, MH
Patricia Rembert	S/95	Kwajalein Hospital Kwajalein, MH
Albina Riklon	S/92, F/92	Armer Ishoda Hospital Majuro, MH
Patricia Robins	F/95	Dept of HHS/Public Health Service, Bethesda, MD
Ivy Springer	F/94, F/96	Kwajalein Hospital Kwajalein, MH
Caroline Tuman	F/96	Resident Nurse Walter Reed AMC Washington, DC
Mary Ulyat	S/96	Private Nurse Upton, NY

#### **PHARMACY**

NAME

Jiri Cizinsky S/94, S/96 Consultant, MIMP

Upton, NY

Blanka Cizinsky S/96 Pharmacy Assistant

BNL, Upton, NY

**ADMINISTRATION** 

NAME

Peter Heotis, MPS S/92, F/92, S/93, F/93, Admin, MIMP (from 1993)

S/94, F/94, S/95, F/95, BNL, Upton, NY

S/96, F/96

William Scott S/92, F/92 Admin, MIMP

BNL, Upton, NY

**TECHNICIANS** 

NAME

Robert Brown, Tech F/93, S/94, F/94, S/95, MIMP

F/95, S/96, F/96 BNL, Upton, NY

Linda Cavaliere, RT F/95 Medical

BNL, Upton, NY

Helmer Emos, Tech S/92 - F/96 MIMP, BNL

Ebeye, MH

Lee Harris, RT F/92, S/93, F/93 Honolulu, HI

John Heinrichs, MS S/92 Medical

BNL, Upton, NY

William Lehman, RT S/92, F/92, S/93, S/94 Medical

BNL, Upton, NY

Fran Putnam, RT S/92 Stony Brook Univ

Stony Brook NY

Tonya Sheppard, RT S/94 Sacramento, CA

Veronica Simpson, RT S/94 - F/96 Long Island, NY

Harry Ulyat, Tech S/92, F/92, S/93, F/94 - F/96 BNL, Retired Crystal River, FL

#### **TRANSLATORS**

Capelle DeBrum, Translator	F/93 - F/96	Bechtel Nevada Honolulu, HI
Elsa Patton, Translator	F/96	Kwajalein, MH
Kosang Mitzutani	S/92	Majuro, MH
Sebio Shoniber	S/92, S/93, F/93, F/94	Majuro Hospital Majuro, MH
Pamela Hazel	F/93	Kwajalein, MH
Max Helkena	F/93	Majuro Hospital Majuro, MH
Estella Leviticus	S/95	Majuro Hospital Majuro, MH
Heddleson Jeadrik	S/96, F/96	Ebeye Hospital Ebeye, MH
Marie Laik	S/96, F/96	Bechtel Nevada, HI
Linda Hall	F/96	Kwajalein, MH

## Appendix B

## APPENDIX B

Individual patient ((Marshallese)) laboratory data collected during 1992 through 1996 medical surveys. (Identification numbers 1 to 86 belong to exposed persons of Rongelap and Ailingnae; numbers beginning at 2102 belong to the Utirik exposed; numbers from 805 through 1578 belong to the Comparison group).

## Abbreviations:

PID = Patient IDentification Number

SEX = 1 - Male; 2 - Female

AGE = years

WBC = White Blood Cell (leukocyte) count/μl

PMN = Polymorphonuclear cells (neutrophil) count/µl

BAND = Band forms/μl

LYMPH = Lymphocytes/µl

MONO = Monocytes/μ1

**EOS** = **Eos**inophils/μl

Basophils/μl

PLT = Platelet count \*  $10^{1}/\mu$ l

HCT = Hematocrit (percent)

REC = Red Blood Cells (erythrocytes \*10<sup>6</sup>/μl)

mcv = Mean Corpuscular Volume in fl (cu. microns)

HGB = Hemoglobin level in g/dl

TSH = Thyroid stimulating hormone level in  $\mu$ IU/ml

prL = serum prolactin in ng/ml

FBS = Fasting blood sugar in mg/dl

HEA1C = hemoglobin A1C (glycosylated) in percent

RES = Random blood sugar in mg/dl

CAL = Calcium in mg/dl

TPR = Total protein in g/dl

NOTES: Series of 9's indicate test not performed or unavailable.

Series of 0's indicate test performed but results below lower

limit of detection.

805	86	ď		ء د	79	78	77	6	; ;	7 .	74	73	1.2		7 1	70			66	65	64	0	, 6	N (	. ·	<b>.</b>	49	48	£	<u>.</u>	л 2	44	42	41		<u>.</u> د	ų O	77	36	34			) i	24	23	21	20	14		-	. ,		15	14	ø	œ	_	. 0	٠,	л.	_	w	2	-	<b>7</b> D
2	· ~																																							_			_	<b>2</b>	_	_						٠,	_	_							٠.		<u></u>	;	SEX AG
ă	, L		,	7	77	73	7 9			40	5	56		n .	40	\$		2	67	39	Œ		,		6	5	54	-		2	70	12	Ξ		ŏ:	7	2	8	6		5 6	<b>&gt;</b> .	4	<u>.</u>	~	c	عه ۱	٠.		۰,	-	œ	G,	8	8			٠,	۰ ۵	9	6	9	9		M
•	•		900	200	000	00	100		<b>-</b>	500	300	0.00	, (	3	900	007	3 .	200	400	00	100		000	500	500	900	008	000	0 0	6800	999	500	200	3 6	20	00	00	00	00			5	00	00	00		9 6		0 0	3	00	0	00	00	Ö	9 6	9 6	5	00	00	00	00	00	į	МВС
	•		•	'n		1.				an.	0			30	N		,	g,	$\sim$	· Œ	, ~		77	999	o.	~	_		_	~	99	-			_	••	_		_	_	_	_						•	-	_	~	•	- 1	_			~ .	_	~	••	••		6210		PHN
Š	0000	, ,	79	0	· c	) ·	3 .		0	0	186		, ,	122	c		>	0	148			۰ د		_	0	c	· c				99	_		<b>,</b>		140		202		,	 	0	0	0		<b>,</b>	> 0	<b>5</b> (	<b>-</b>	0	0	0	0	· C	<b>,</b> c	ه د		9			1416		0		BAND L
	00000	~	•	-		٠.			~	9	Œ	•		œ	-		~	œ	-		, ,	•	_	v	·	•			_	_	99	2300		••	٠.	_	_	_			_	_			_					~		~		_		-			$\overline{}$			3990	1890		,үнрн
,	66666	n	9	-	• 4	•	; •	9	ū	0	-	, ,	_	4	C	3 (	208	444	40	1 -						010					99								a c	3							_		504					٠.		٠ ٠		_	`~	`			90	,	HONO
	99999	395	79	-	1 6		د	146	450	450	. 0	0 .	215	61	7.70	276	156	999			973	204	462	99999	0.52		,	304			9	4 6								٥	0								- 1		~	_	0 0		7 6	120		1488	72	456			018		EOS
		79			- 1 - 1	٠.	-	w	75		٠ (		0	2	٠,		2			<b>&gt;</b> 1	J	•	6	6666	4		9	2	Ò		4		Э.	114	0			•	, ,		0	0	8	,	_	_	_		0		c	•	3 (	<b>&gt;</b> (		0	Q	93	0		۰ د		<u>-</u> د		BASO 1
	324	220	286		, r		259	263	180	107	3 6	ا د د	200	402		217	205	j		7	5	5	0	6	. 0	,	-	9	5	=	, ,	5	ĕ	Ë	5	3	,	5 -	3	-	5	4	Ü	1	3 .	7	o,	0	0	ū	_	3 4	0	9	9	0	ഗ	4	G	•	•	<b>,</b>	2 7 6		PLT
	37.6	41.2	9/.9				•	•	•	٠		44.7	•	•	•	•	٠		• :		5	8	9	•	``	3 (	ָ פ	o	~	~	, ,	٠.	_	~	5		` .	,	9	5	٠.	2		• •	~ ;	G.		4	5			٠.	٠.	Ξ,		-		39.2	•	•	7	۵ 4 ۵ 4 ۱ د	4		HCT
	4.62	4.59	. L U		_	_	•					5.02		٠		4.28	4.20		•		•	٠	٠	٠	•	•		•	٠	٠	٠		3.73	•	٠	٠	٠	. •	•	• .	:_	:	:	2 0	_ :	٠.	٠.	:	٠.	٠.,	:	. :				•	٠.	•		•			4.97		RBC
	81.4	90.0		٠:	7	Θ.	۳	9	. 7	•	2	89.1		٥	ם	_	:	, ,	1010		:	٠	٠		٠:	•	~	~		٠.	٠.	9 666	92.8	96.3		٠.	٠,	- 7	:-	:-		٠		1010		•	•	٠	74.9	٠	٠				•	•	•	•	٠	•	•		89.3	•	HCV
	12.2	12./			17.	14.	13.	15.			-	15.2	15.			•	٠	•	) •	13.4	11.6	17.1	10.0			- - -	. 5	13.2	•		л '	9	N	٩		<b>3</b> F	٠,		13.0	N	C		n 4	•	15.5	15.5	13.2	15.6	15.3	12.0		٠ ٠	12.8	13.6	12.7	14.4	14.4	. α	, ,	, د		<b></b>	15.3	14.6	HGB
	999.99		_						, 4	5 :	-	3.30	•	. ;		٠	٠		17.30	•	9	21.	٠٠			7.40	•	. 50	٠	5		. 50	1.30	. 1.2	•	•	•	•	1.50	•	٠	. •	. •	•	. 40	•	:		:		•		•	11.50	:	:	:	:					999.99	•	TSH

1035	_	-	. ~	~	- •	- •	_	_	_	~			^	~	•											0 0	ж с	D C	в с	-	_ 0							*	·	~ ,	~ .	~ .	~ -	~ .	$\sim$ $\sim$		96		J -		811		PID
2	_	~	۰,	<b>-</b>	~	<b></b>	_	2	<b></b>	2	2	2	<b>-</b> -	_	2		~	<b>~</b> 1	<b>.</b> ,	<b>.</b>	<b>.</b> .	J F	٠,	<b>.</b>	<b>.</b>	<b>.</b>	<b>2</b> •	٠,	٠,	<b>-</b> •	، د	<b>.</b> .	<b>.</b> .	<b>-</b> د	٠,	· ~	2		_	<b>2</b>	⊷ ,	٠.	<b>~</b> +	<b></b> •	<b>,</b>	<b>ა</b> ►		<b>-</b> ,-		<b>J</b> ►	- ~		SEX
41	81	58	4	<u>س</u> 8	46	49	60	<b>&amp;</b> 8	64	40	<del>د</del>	39	67	61	77	46	59	67	7 .	۵.	<u>.</u>	7 0	) ·	5 U	ب بر ا 0	л ( ) і	62		л ( Э (	л ( 0 •	بر 1	, v	n 0	J N	3 2	, C	59	62	59	58	5 6	ים א טוני	J1 (2	 	лu	n 2 > c	> 4 > C	y r	- ·	>	38		AGE
5	4	5	7	2	4	8	Ξ	Ξ	9	۳	9	9	1	8	20	60	8	60	9 1	5	2 :	58	2 6	2 6	5 6	3 8	20	9 6	58	5 6	20	36	5 6	5 6	· c	; =	ŏ	ö	7	ö	5	0	50	50		5 6	58	5 6	5 6	2 6	8400		мвс
Ν.	w	4		9	00	0	2	8	4	96	2	ш	2	9	2	6	8	8	20	90	5	30 0	ב ו	<u>ب</u>	2	9,	59	20	-	3	50	0 0	ם נים	. U	7 6	; =	ă	Š	Ξ	ö	9	7	3:	3	ב ב	2	9.	., . .,	ית טונ	N C	4536		PHN
0		55			0	264	51	0	0	146	0	0	0	0	0	0	0	0	0	0	0	۰ د	<b>.</b>	0 (		80	0 (	0 (	0 (	<b>.</b>		00000	<b>-</b>	<b>5</b> 6	<b>.</b>	<b>,</b>		0	0		0			96	0 0	<b>,</b>	<b>o</b> (	5 6	<b>-</b>	۰ د	84		BAND
0	7	0	. 0	·	-	8	2	u	-	9	7	75	5		2	2	6	5	8	20	יים	12	30 (	3	8 2	96	2	ω.	2	ווט	5	֓֞֞֜֜֓֓֓֓֓֓֓֓֓֓֜֜֜֜֓֓֓֓֓֓֓֡֜֜֜֡֓֓֓֓֡֓֜֡֓֜֡֓	ם נ	ם טינ	9 4	9 0	, 6		52	5	2	יבי	2	8	9	4	4	7 :	ى د ت	د سا	3276 1716		ТАНЬН
255	88	220	527	1408	416	704	408	567	177	438	384	158	648	686	310	56	490	228	138	244	318	497	168	480	171	640	248	621	357	474	18	66666	260	205		100	110	1350	582	651	198	378	ა ა ა	672	76	384	426	4 1 2	٠.	148	336 208		HONO
	220	, ,	•		936		0	324	~ 1	73		632	0	0	N)	CD.	•	w	ıπ	_	_	பா	_	Φ.	•	N	N	un '	un i	LTI I	18	9	ο,	y,	0 4	<b>~</b> •	აი	4650	8	93	396		un i	480			1349	i	,	Ö	168 104		EOS
_					104		51	0	0	0	0	0	243	98	62	112	70	152	69	61	106	71	0	192	57	0	0	138	0	اسا	12	9	en e	61	 	102	• • •	600		0		63		0	0	128	0	0		74		)	BASO
2,0																																																			309 223		PLT
92.3		6	. £	2 0	37	5	38	ა 8	۵	41	41	40	4	4	37	9	37	36	37	6	ب 8	<u>~</u>	2		6	42	42	44	49	8	ب 8	4	37	ب د سا	A .	ے ر د	ט ט	42	50.	52.	46.	42.	4	42	32	9	٠	4	8	4:			HCT
4.92					1	5.11	4.17	4.54	4.58	4.57	4.61	•	•	:	:_	٠	: .	•	:.	٠.		:	•		٠.		:	•	٠,	•								٠.	٠.		•				3.64		6	0			5.12		RBC
00.0	90.0			90.4	85.	. 8	~	·	_	0	9	. 2	•	. س	Š			·	5	5	·	•		٠.	:		•		•		7	Φ:					л:	٠.		•			.5	ω.		5		ω.	•	٠,	95. 92. 0	•	MCV
10.	٠,	، ز	با د	ە د		. 6	N	·	س ،	w	_	س.			-																																				12.6 16.2		нсв
777.		۰.		000	. 666	999.	999.	999.9	999.9	999.9	999.9	999.5		999.9	999.9	999.9	999.9	999.9	2.4	999.9	999.9	999.9	999.9	999.9	999.9	999.9	999.9	6.7	999.9	999.9	999.9		999.9	999.9	999.9	999.9	0,000	000.3	999.9	999.9	999.9	999.9	999.9	999.9	999.9	999.9	999.9	ເກ	999.9	999.9	1.60	•	TSH

-	_	_	_	٠.				_,	_ ,		2144	_	_	-	•	•	-	-	• •	• •	- •	- •	٠,	-	_		•••	••		_	_	=	o.	1573	1572	1567	1564	1560	1559	1558	1557	1556	1552	1550	1549	1548	1546	1542	1541	1529	1525	1524	1520	1519	1036	PID	
2	2	_			٠.	<b>-</b> ,	, ب	<b>&gt;</b> :	<b></b> 1	-	<b></b>	••	_	2	2			, ,	ء د	ა :	<b>.</b> .	، مــ	<b>-</b>	_	~	2	_	2	<b>—</b>	<b>-</b>	8		N	<b>,</b>	-	N	N	N	2	2	<b></b>	2	•••	-	-	2	_	2	2	<b>-</b>	2	<b>-</b>	2	<b>,_</b>	<b>,_</b>	SEX	:
42	67	47			، ب ا ه	UT I	50	46	8 2	70	5	41	<u>۵</u>	73	4	7 6		כי	2 0	5 6	<u>ک</u> ر	9	ب 8	78	42	41	85	63	42	90	61	48	42	42	44	3 8 8	هـ س	8 9	39	42	44	47	62	49	39	50	78	39	64	5	49	49	61	49	0	AGE	t
400	200	/00	9 6	000	800	300	900	500	000	300	500	000	400	000			5 6	0 0		000	300	00	00	00	00	00	00	00	00	00	00	00	00	0	00	00	0	00	00	00	00	00	00	00	00	00	00	8	00	00	00	00	00	5600	00	WBC	;
-	- 1			_	~	_	<b>~</b>	~	~	Ф.	_	-	_	, ,-		, ,			~ .	_	~	_	٠.	_	_	•	-		_										_	_		~		_	_						~			3696		PHN	;
_			٠,	9	58	0	0	0	0	53	0	0	802			<b>.</b>		2 1	52	0	83	0	0	0	0				, c	87	, ,	o C	, _					. 6	110		2 2	3 -	• •		,	232			106	0	0	212	0	56	75	BAND	; ; ;
2360	199		- A	20	 		24	32	28	<b>-</b> 5	28	24	2	3 6	) t	ى ر د د	، ر. ا د	- ·	23	22	39	21	43	19	36			) e			) L	3 6	2 2	ب ا	2	5 6	2		2	9	200	2 h	2 4	٠ د د د	2 2	222	41	4	498	206	126	25	269	128	2700	FILTER	YMDE
9 230	0 0			٠,	.,		_	_	~				. a	n 4	٠.	<u> </u>	2	فعا	~	2	_	9	7	w		L.			<b>.</b>	J K	٠	4	. د	. 0	٠ د	ي ب		٠.	٠,		. 4		<u>ء</u> د	ن د	. 0	٠.	α.	٠ س	. 0	. 6	-	: >	۳ ا	سا د داد	300	1000	K O N O
200	3 6	ာ ဗ	0	112	348	73	237	195	180	530	195	. 60	, ,	100	560	156	474	808	208	1230	0	92	121	4		0201	2 6	s c	1057	٠.	1 1 1	- - - - -																	2 2					87.7	75	•	ROS
- 7	n -	٠.		0	0	•	79	L			ċ	120	3	<b>.</b>	<b>-</b>	0	0	9	52	N	w	2	-	۰٥	, ,	s	<b>.</b>	; د د	, , , , , , , , , , , , , , , , , , ,	5 0	<b>.</b>	<b>D</b> i	- 200	<b>.</b>	<b>5</b>	-	,	_	, -		Š				- ·		ر د د		106	٠.				<b>1</b> c	150		BASO
,		31	12	25	22	269	188	286	175	2 / 9	2 2	. v	9 6	9 6	321	403	304	321	222	200	327	240	3 2 5		1 6		A 4 7	) t	240	ر د د د	20.5	217	377	3 K	, v	) ( ) (	, c	) t	3 L	بر م	2 C	ر د د د	א מ מ	22.5	777	2 6	) L	1 0	7 7 7	4 6	) L	7 6	3 6	707	213	1	114
	3 6	40	<u>4</u> 5.	50.	44.		ع ر	. L.	ما د عد د	4		3 4		51 .	٠ م	37.	39.	42.	41.	37.	38.	44.	. U	1 6		- 6	2 5	ب د د	ت	5 1	ا بر او	ب 8	47	ָ מ	3	8 9	ب ر ج بر	ب 0	ه د د	3	4	2	3	4	ָ פּ	- :	3 d	7 (	л <u>-</u>	• •	٠ د		֓֞֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓	5 0	48.0	;	HCH
	<b>A</b>	_	<u>-</u>	ū	ŭ	ء ،	٠.	۱ د	•	٠	. 4.	٠	•	•	•	•	•	•	•	٠	•	•	•	•	•	•	•	•	•	•		4.24	_ `		_ :		_ `	_ :	_		_		3.96	4.72					. :	. :					5.53		RBC
							0 4		9 4	2 4	0 Y	D C		92.	94.	86.	91.	87.	82.	8 /	9 0	, ,	9 9	0 0		75	77	107	87	8 4	91	9	95	90.	9	30 (S	86	87.	97.	80.	89	92.	94	88.	88	88	9	9		2 .	<b>,</b>	۵,	۰ ۵	<b>.</b>	90.0	ı I	HCV
,	0 14	7 14.(	8 15.8	1 / / . :								<u>.</u>	س	16	=	13	<u>.</u>	14	-	1.2	; ;	; ;		<u>.</u>	_;	ب	<u>۔</u>	01	<u>۔۔</u>	16	=	13	17	ب س	6	16	12	ب س	بر س	_	-	14.	بب س	 	 	14.	99	6	5.		-	: •	7 :	•	17.0 16.0	) •	HGB
		_	_		·	٠.	- :	٠.	,,	000.	•		999.		۳.	-	-			٠.	٠ -	- :	٠,	. س		2	<u>.                                    </u>	w •	۲.	2.		5	•_	999.	999.	999.	999.	<u>-</u>	999.	999.	<u></u>	999.	٠.	999.9	99.	99.	99.	99.	99.5	9 6	99.5	99.5	99.5	99.9	999.99	) )	TSH

2277	27	27	27	26	26	26	25	25	25	25	25	2	9 6	١,	) L		3	2 1	ا د ا ب	ا د. ا	2	23	2	23	22	22	22	22	2 2	4 5	, c	2	2 ~	2 2	• •	2 2		2 0	20	2 0	2 0	ב כ	ָ ע	5 v	<u> </u>	<u></u>	3	8	17	7	7	7	6	2166	<u>.</u>	PID
21	_	-	<b>-</b>			~	<b>,_</b>	~	2	۰ ۸				ء د	<b>.</b>	٠,	٠.	<b>-</b>		-			2	2	N	2	2		۰ د	) h			<b>.</b>	۸ د	<b>.</b>	, c	۸ د	<b>,</b> ,	<b>,</b> –	• •		• •	<b>,</b>	4 C	٠,	۰,	(	<b>~</b> :	-	_	2	2	<b>-</b>	<b></b> ,	<b>N</b>	SEX
			37	37	63	38	5	Δ. W	42	ū	48		n 4		3 6	- :	ъ.	49	9	50	9	ô	39	50	56	6	42	6	ů	. 4	0 0	ט י	7 2	) <u>-</u>	3 6	ب رد د د		<u>.</u>	1 6	2	3 0	א נ	3 6	7 6	3 (	9 1	4	90	48	38	50	6	52	75	70	AGE
7200	5300	8	5400	9	-	30	20	00	30	9300	20	2 6	ى د 5 0	n (	ט נ	SS	5	20	70	9	0	0	10	70	6	70	80	99	9 6	9 0	2 6	9 0	9 0		3 6	3 2	3 6	3 8	3 8	3 5	9 6	ט כ	ת סכ	֓֞֜֜֓֓֓֓֓֓֓֓֓֓֓֓֓֓֜֓֜֓֓֓֡֓֡֓֡֓֡֓֡֓֡֓֜֡֓֡֡֡֡֡֡	2 5	2 6	30	6300	2	9	6	9	0	8900	10100	мвс
4464	7	59	5	9.2	0 2	<u>سر</u>	u A	_	ŭ	2	81	9	) P	) t		- 6	<u>ہ</u>	4	0	8 9	47	62	26	85	75	78	92	99	0		ع د د د		, .	7 6	יונ טינ		, ,	ع د ع د		, c	) (	5 0		ب ر م	Ś	"	2	w	58	57	S	4	55	7031	-1	PHN
0			<sub>5</sub>			. 0		. 0	. 0				,		۰ د	<b>.</b>	5	0		66	0	0	0	0	0	w	666	99999			ט ת	1 6		J	ء د		<b>,</b>	2		, ) (		<b>,</b>		<b>5</b> 6		5 6		0	0		132	0	0	0	101	BAND
<b>CD</b> 1	<u>~</u>	8	2 1		4	2	1	4		9	-		· ·	3 4	2 6	2 6		<u>ب</u>	8		89	8	2	77	20	39	8	9	2 6	ט נ א א	3 6	4 6	• 0	90	9 6	9 0	3 L	<u>ء</u> د		9 6	א כ	> <	2 2		- 9	<b>a</b>	∞ .	ä	w	Ħ	u ک	ü	-	1602	-	ТХМРН
360	•	a	. ~				L	ι Δ		L LT			<b>7</b> -	٠.	- 1	٠,	3	J	8	9	9	8	8	8	N	0	•	9	9 9	4 0	) L	• 0	n c	<b>o</b> c	<b>5</b> C	נים עינים	5		10	9 P	s c	n v	0 0	,		un •	<b>.</b>	_	ы	_	S		_	267	404	HONO
72	159	70	162	44	185		N	0	Š	372	سا 1		<u>ه</u> د		<b>.</b> (	20 (	8	8	291		6	w	4	-	N	03			000	JU	n v	•	Ü	ے د	> F	. C	j L	л н		<b>5</b> C	> ×	٠.		ა .	79	189	0	63	8	w	39	6		0		EOS
	106	0	4		, <u>-</u>					. 9	م ہ	٠.		٠.	بر س	<b>.</b>	56		97	132	0	0	0	0	0	0		66666		<b>.</b>	<b>.</b>	<u>.</u> .	, L		ء د	ء د		1 1		,	<b>.</b>	<b>,</b>	<b>5</b> 6	<b>-</b>	۰ د		53	0	176	0		258	70	0	0	BASO
285	S	0	U	١ ~	ט נ	1 2		. 0	•	. 0	٠,	- 0	<b>~</b> •	J (			₽	9	9	0	5	8	8	~	6	9	<b>~</b>	v	> ►	- 0	<b>ν</b> ο	h	ى د	J	u r	o c	<b>D</b> >	<b>~</b> <	9 0	9 0	ם כ	ے د	> د		o ,	•	9	245	•	w	0	S	-	325	271	PLT
34.9		50.0	` :	•	٠.	35.0		٠.	``		٠.	• :	2 .	. د	ъ,	æ :	·	•	•	5	7	:-	•	·	0	9	à	. v	٠.	٠ ز	л ч	9 0	P C	<u>ه</u> د	۰:	٠,	٠:	٠,		ء د	<u>ئ</u> ے د	٠,	 	٥,	8	: س	7.	N	?	9	u.	:	5	42.9	ω ·	HCT
	ü		·					۵۰	:		-		, a				8	5.26	0	-	0	_	CT.	5.21	6		4.01	١ v		<b>D</b> 0	<b>3</b> 6		٠.	D 4		) d	n e	ب د د د	2 6		7 . 4	2 2	א א א	0.0	σ.			3.35	LT		٠			4.85	4.15	RBC
9	ú	85.5	٠			88.5	82.2	2 . 2	79.7	7 . 7			B .	76.	94.1	88.2	90.1	85.3	7.	9	92.9	<b>.</b>	79.0	<i>س</i>	88.5	~	٠,	٠,٠	٠, د	ه د	٠.	• •	ي	٠ :	•	200	٠:	- 0		ع د •	,	3 C		- :	2	6	87.8	•	٠.	6	9.	88.1	87.1	8	80.8	МСЛ
10.8	15.2		•							٠							•	•	•	•	•	-	•	•	14.0	•	•		5 :				•					•	•	•	•	•					•	•	٠	•	•	•	٠	13.6	•	HGB
1.37	N	:	:			. :		,	٠.	25.10	. :			1 30		<b>.</b>	N	cn	ð	7	1.80	. 9	L	·	6	1.50						n -		_ :	٠.	- ·		٠,	ے د	× •	s e		4	. م			C.T.		œ		-	LT	٠.	4.50	. 9	TSH

1 38	SEX AGE
5500	мвс
3685	PHN
165	BAND
1155	LYMPH
ទ	HONO
275	EOS
165	BASO
264	PLT
264 45.9	HCT
9 5.20	RBC
88.3 16.3	HCV
16.3	HGB
1.23	H.

PID 2548

00000000000000000000000000000000000000
מ מוווון מוממט וממ בו בממנים במונים בממנים ממנים במונים בו במונים בו במונים X
4 04r44r4bbbbbbbbbbbbbbbbbbbbbbbbbbbbbbb
5300 5300 7200 7200 7200 7200 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400 8400
289648 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000
1 1 0 5 6 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9
22222222222222222222222222222222222222
300 300 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 31
# # # # # # # # # # # # # # # # # # #
9 7 8 5 4 4 4 6 6 1 4 5 6 6 6 6 7 5 6 6 6 6 6 6 6 6 6 6 6 6 6
72222222222222222222222222222222222222
44444444444444444444444444444444444444
54555000000000000000000000000000000000
998889988898888999989989989989989989999
2 1 1 2 1 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2
88998899999999999999999999999999999999
# ####################################
8 4
X
α 11
# # # # # # # # # # # # # # # # # # #
\(\frac{\pi}{2}\)
7HS7
>H 0 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 -

1563	1556	1553	1552	1546	1533	1524	1520	1519	1506	707	1000	1001	1001	998	993	981	980	9/1	966	965	960	959	955	944	042	928	934	932	926	925	9 14	911	896	88	882	881	0 70	867	865	864	æ α .π ε	00 4 44 7 44	843	840	9 0		
-	2 ~	, ,_	۰ ۔	<b>-</b>		<u>-</u>	~	, س	<b>.</b> ,		<b>.</b>	<b>ي</b> د	- ~	ه د	~	-	~ :	٠,		۰ ~	2	2	2	<b></b> ,	N +	<u> </u>	<b>,</b> N	, <b>2</b> 2	2	N F	- ~	2	N 1	- د		⊷ ,	<b>پ</b>	۰ ہ	2	<b></b> (	2 +	- 10	<b>N</b>	<b>1</b> 2	XEX	:	
7	<b>4</b> 0	•	، ب	9	0	0	2	0	σ.	•	ω,	~ ~	. · ·	3 0		~	_	•	-	_	, ,	_	•		_		_		-																	l I	
-	5100		~	~ ~		· vo	173	w.	w	w	un v	~ .	$\sim$		,	_	•••			-	_	_	•	_				_	_	_		_	~ .		_	$\sim$			_	_	_		-	_	~ ~	;	
	2754																																													; :	
	0				Ý	2			99	99					,							_				99		~	•		_														BAI	2	
u	1887	ر د د	1	2 !	. v	2 22	24	<u>,,</u>	99	99	24	27	29	ب د	ى د - د	, , 5	41	24	2:	ه د پ د	ى د ت ر	, 18	42	14	20	29	2 6	) L	2	26	2 4	26	35	29	212	22	299	196	່ພ	4	339	<u>س</u> د	211	20	260	-	
	7 102	_			., ,	2	_	N	99	99	u	<b>.</b>	<b>.</b> .	_		۵		w :	<b>.</b> .		~ ~	. ~	,	-		<u>.                                    </u>	٠.	•	ب د	w	_	u	۳.	w r	ے د	<u>u</u>		2 5	ب د	<u>5</u>		N	, N		100	Š	
	2 306			_		0			99	99	N	_	_				N	5	N	,	ى د			_	w	2		, ,	ه د	~	c	<u>,                                     </u>	_	٠,	ے د		4	<u>.</u>	- N	2	17	۳	11		S C		COMP
	51				,	٥ _			99	99												,_	•				,	<u>.</u>	ے د	•		2	•		<b>.</b>		_		-	•		~1	-			B A S	UTER
_		L. 1.		1.1			. N	س د	. •	N	~	2	_	2	N :		, ~	2	w	~	<b></b> (		ه د	, ,	~	2	_	ء ب	بر د	ي.	= :	2 2	N	2	~ ·		'n	2	, r	ب ا د ا	2	2	2 .	ر د د	27	14	LIST
4		<u>, , , , , , , , , , , , , , , , , , , </u>		2	٠ د د	) L	2 4 5	46	9 9 9	37	44	39	5 28	7 42	ა ა	ب م م	6	40	46	39	38	ر ار د		ıω ıσ	<u>س</u>	48	36	3 2	77 K	39	40	ه د 2 ه	. <u></u>	38	ء ہ و	47	9	14	ب د د	2 29	29	41	ص د د د	າ ຜ ວ	4	Ħ.	INGO
ع	5.2 3.9	2 5	0 2 2 4	6	0 4	57 Y	י הי	, 0	. 9	6.4.	. 5	7 4.	ω	5.	۰ د	- U	٠.	7.4.	5	ه.	٠.		- c		. w	5	4	ω (	ء ب	ه.	_	4		۵.		n U1	4	4	<u>.</u>	ما د د	س د		<u>م</u> .	ء ہ	UT .	<b>7</b>	F 199
Č	~ 0	Δ.	٦ ~	100	2	ى ھ	J F	. (6	שינ שינ	, c.	. w	. ~	, ω	7	٠.		•		•	_	•		-											_		- ~	. ~	_	٠.	~ ~			<b>.</b>	ο σ	. ~1		•
	92.9 91 n	-11	٠, -	·m	-1	CO N	ა c	3 0	SV	v	2.9	6.0		0.4	2 . 5				.9	.5	0		7 .	, L		. 9	6	. 2	0 4		-	_ ;	, <u>-</u>	<u>:</u>		د د	. 6	-						٠,		ACA	RAW D
	12.3	13.2		13.0	12.6	15.1	16.4		99.9	20.0	ھ د		. 0	•	w	<b>~</b> (	<b>~</b> ~	-	5	2	<b>.</b>	$\sim$ $^{\circ}$	ء ب	3 1	, <u>, , , , , , , , , , , , , , , , , , </u>	. 5	~	_	~ ~	~ ~				13.3	_		. –	_	15.7	1.0	0	13.4	14.3	N N	5.5	HGB	ATA
•	2.2	. 9	 Bo v	1.9	99.99	3.38	1.6.		•	5 <b>:</b>	•	•	xxxx	•_		1.21		4.36	•	:_		• . :	_ :	:	. 2	1.85	:	:		3 N		<b>N</b>	<u></u> α	. 67	-		٠.	2.17		2.24		1.36		. 24	1.20	TSH	
,	9.9															9	o 4		, ,	9	9	•	ω,	ه م	<b>20</b> 0		<b>.</b> .	9	9	» «	<b>.</b>	8	۷ م	9	9				8.6		ه د د	. 6	9.8	9.7		2	
1	6 L	. 4	ω .		99	٠٠	د د	u		0 2	s	. <b>.</b>	- <u>-</u>	ح. د	<u>-</u>	۰	د س	٠.	. ~		_	۵	ا هـ	t	، د	ے د	. س	_	u ر	L	ıω	4	<b>س</b> ر	حه د	ω	<b>س</b> ر		. ب	۵.	ω <u>.</u>	<i>يا</i> در	ے د	Ç,	ω <u>.</u>		70	
,																																										. u		<u>ي</u> .	حه س	170	
		. 5			•	-				6		٠.	p ~			.9	<b>:</b> :	, ,	. د	, 7		٠.	. 9	7		٠,٠	۵.				. ·			o .v		(	» c	. 4	·o	7	۵ د	> œ		6	א ה	LB AL	
		س	. 2				. 2		2	<b>X</b> :		. د			٠ <u>.</u>	. 2		٠,	٠,		. 20		<u>.</u>			٠ <u>.</u>	٠ نـ	ن. س	۳	. د					.2		٠,	سا د	٠ س	ພໍ		ىن ب	, <b>.</b>	wi	٠ س	ست. ح	
		n œ	. 7	. ,	2 X	.6	8	&	6	Ž:	, æ (		٠.	, v	, _	5	. 7		• :		. 0	&	. 7	&				. 0		7		.7	7	- 6	. 6	. 7	7 0	, O	•	6	. ;	٦ œ	, 60		» œ		
			. 8		. v		B	. 9		99.9		. 9		» v		. 8	. 8	 			1.0	. 8	. 8	1.0	1.0				1.0	. 7		1.0	. 7		. 7	. 9	 B			&		я .	, <u>.</u>	. ;	, .	BET	
	2.1											B		7 .		. 7	. 2		J1 1-		•		.9	-	.9		٠.	ی د	Ġ	0	<b>.</b>		ω.		`-i	2	٠.	<b>4 4</b>					. 0	2.2		- 33	
	0	o ⊷	0	0	0 4	, <u></u>	0	0	0	9	0	0	0	0 0	<b>-</b>	0	0	0	0 0	<b>-</b>	9 0	0	0	0	0	0	<b>-</b>	<b>-</b>	0	0	0 0	0	0	0 0	0	0	<b>,</b> (	<b>-</b>	0	0	0	- ۵	• 0	-	<b>-</b> c	BSA	
	0	<b>-</b>	0	0	0 4	. 0	<b>,_</b>	0	-	9	0	0	0 1	<b></b> .			0	0	<b>-</b> (	<b>-</b>	<b>-</b>	0	, <b>,</b>	0	0	، مسو	<b></b> ,	<u>-</u> c	<b>س</b> ر ر	. مب	<b>⊷</b> (	0	-	۰,		0	0 1	<b>-</b> c	<b>-</b>	0	0	<b>-</b> c	<b>,</b> 0	0	0 0	D	
	-		۰ ــ	0	<b>.</b> .	۔ ہ	. 0	-	<b>,_</b>	9	<b>-</b>	0	0	0 (	<b>&gt;</b> c	0	0	<b>-</b>	<b>-</b>	⊶ .	٠,	۔ و	٠, ـ	0	0	0	<b></b> (	<b>⊃</b>	• 0	0	p-0 \$		-	<b></b> .			<b>-</b>	<b>-</b>	> ⊷	. 0	_	<b>-</b> •		. 🟎	<b>⊷</b> ⊦	AHBC	

15772 15772 15772 15772 15772 15772 15772 1100 17772 1110 100 100 100 100 100 100 100 100 1
B 22 22 22 22 22 22 22 22 22 22 23 24 24 25 26 27 27 27 27 27 27 27 27 27 27 27 27 27
本 , Daadadaaaacce B Daadaacaacce B Daadaacce B Daadaacce B Daadaacaacce B Daadaacaacce B Daace B Daa
129 644 147 147 147 147 147 147 147 147 147 1
WBC 2000 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
711094 31094 40160 31080 715080 71680 71680 71680 71680 71680 71680 7178 7178 7178 7178 7178 7178 7178 71
9999 5 8 8 9 7 7 4 9 6 8 8 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9
0148076376 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076 0148076
00000000000000000000000000000000000000
$\begin{array}{cccccccccccccccccccccccccccccccccccc$
BASO  . 0 0  . 0 0  . 1 388  9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9
7 3 2 2 4 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
614498894497979747974889749979797979797979
<ul> <li>Θ</li> <li>Θ</li></ul>
99999999999999999999999999999999999999
8 200700 X 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
0 o o o o o o o o o o o o o o o o o o o
₽
#BS > 7
7HSA
AH BC C1001111191101111111111111111111111111
 D.O.

PID 22117 22217 2224 2224 2224 2224 2224 22	
0 H H H H H H H H H H H H H H H H H H H	
K DO 90 90 90 90 90 90 90 90 90 90 90 90 90	
11 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	
8411060000000000000000000000000000000000	
PHN 5548 5130 10816 4560 4560 55704 5572 9999 9 9 9999 9 9 4988 4148 4148 4148 5605 5605 5605 5605 5605 5605 5605 560	
BAND 644 769 169 9999 114 114 68 68 68 73 73	
FYMPH 1347H 1387 21176 21780 21081 17180 11716 21666 28660 28660 2860 21108 21184 21184 21184 21184 21184 21184 21184 21184 21184 21184 21184 21184	
HONO 89 2564 1304 1304 240 1172 1172 1171 1168 1168 1168 1168 1168 1168 1168	
9 11 46 9 11 90 9 10 10 10 10 10 10 10 10 10 10 10 10 10	כטחד
9 9 9 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	TOTE
	2
0000712447278714097745900000000000000000000000000000000	
	(
45655444554493445544453344 	,
911.993.5 93.5 93.5 93.5 93.6 88.6 88.6 88.6 88.7 99.1 99.1 88.6 88.6 88.6 88.6 88.6 88.6 88.6 88	
11111111111111111111111111111111111111	
99.99 129 129 129 129 129 129 129 129 129 129 129 129 129 129 129 129 129 129 129 129 129	
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	
PH	
88 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8	
XX	
X	
99.99	
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	
HBSA 000000000000000000000000000000000000	
AHS 0 SA 0 SA 0 C C C C C C C C C C C C C C C C C C C	
же 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	

822 823		• <	ο α	0 0	o 0	o c	» ·	79	77	76	75	74	73	72		: 2		, 0	n (	л <b>.</b>	D- (	ب م	6	5	49	48	47	a. U		> . > !	2 0	40	ა 9	37	36	u	27	24	23	22	21	20	19		; =		. L	n d	•	0 0	o <b>s</b>	J (	אנ	.n. c	r	v	PID	
<b>-</b>	٠.																														<b>,</b>				_												- •	- •		•	<b>.</b>		<u> </u>	٠,	<b></b> ,	-	SEX /	
5 4 12 6	2	<b>.</b> 6	òć	<b>.</b>	. נ	ָ מ	20 0	75	20	50	5	5	58	47	. 0	\ C		л ( Э (	n 4	A :	70	75	48	47	56	5	. <del>.</del>	: :		4	42	69	54	60	47	141	66	5	<u>م</u>	6	2	6	ů		` £	3	70	3 2	2 0	9 4	A :	7 4		4;	4	4	AGE	
4200	Э С	3 6	<b>,</b>	פ פ	~ (	9		•	0	0	w	w	N	-	,	3 (	n t	2	0 :	٠	8	9	Ξ	5	4	5		2 0	2 5	2	8400	2	7500	2	2	2	9	6	5	0	0		•	•	<b>\</b>	π t	2 5	2 6	2 1	2 5	٠,	2	2	5400		6900	wвс	
2604		ر د	3 10 10 10 10 10 10 10 10 10 10 10 10 10	3 1	. ت	، د د	9	0	69	2	76	21	7		ם כו	9 6	,		3 1	5	$\simeq$	~	ä	2	~	-		::	- :	28	$\simeq$	3	ă	ũ	6	9	7	ū			v	ÿ	ō	5 4	ŏ		7 F S P	2	2	Ξ:	_	ž.	3.	۳.	7670	=	PHN	
0.6	٠,	,	99999	<b>.</b>	<b>.</b>	<b>.</b>		256	0	0	93	_					00000	•	99999	0		99999	0	0	_			,	00000	999	84	44	99999	42	0				. <		۰ د		777	00000	0	<b>.</b>	٥ (		88		0	6			99999	0	BAND	
	- e	٠	ہ بہ د		19	27	22	25	13	23	22	١.	, <u>, , , , , , , , , , , , , , , , , , </u>		- 9	2 !	٠,	9	20	N	_	≘	=			-		Ξ:	7	~	2	5	Ξ,	2	56	76	u	, 0	, L	, p	• •	# F	5 6	7 1	л d	4	2170	9		6	6	8	7	2052	2124	1794	ГХНЬН	
8 4	8 U.	644	268	205	332	232	189	320	392	560	93		7 1 0		_			434			61							•	•		336	-		•		276			1 0	5 4		•	~ (	<b>-</b>			_	_	_			~		~	826	207	MONO	
294	<b>*</b>		469						112	350		101				-	_	248			0	.,	648	_		`		1840		•	420	_	40	O	ď		2 2	3	Ĺ	n 6	ع د	1 2 2		9	æ (	5	186	_	ð	2	7	ō	S		826		EOS	
42	150		99999	0	0	0	0	64	56	70						7	110	12	99999	67	122				, 4	n 6	את מנ	92	7	99999	84			1	2 6	3 -	761		<b>.</b>	٠ د	<b>-</b>	<u>.</u>	9 6	6 1	168	0	0		99999		186	6	99999		236	0	BASO	
192	248	229	282	263	190	138	263	279	234	169	223	, ,		3 0	9	206	191	203	181	261	196	189	79			• •		_	_		- •	_	1				٠.			. n e		_		•	-1	_	~	1.3		•	_		S	202	0	188	PLT	
42.8	•	7.	•	<b>.</b>	•	7		5	38.6	2.	•		٠.	٠:		6	9	9	7.	•	6	0	34.2	٠٠		ى د	٥.	7	-	8	39.3		` `	٠.	•	٠.		•		л :		-	7	•	œ ·	7	•	9	0	•	•	•	•	•	47.5	•	HCT	
4.67	4.96	4.27	4.63		5.21		٠.	•							4 . 2 1	3.89	٠,99	4.19	4.22	3.58	3.94	4.64	4.06				_ ,				4.11	•	. :			٠.				<b>3</b> 1	· C	•	9	0	4.46	Φ	4	4.34	0	4.91	4.01	3.97	4.92	4.99	5.35	4.62	RBC	
-	7	7	80.7	~	9	7	0	8	7	-	۰۵	٠ د	9 4	•	8	u	9	٠.	9	8	ü	`~	•	٠.	•	٠,	•	S		٠.	S	٠.	יי	٠.	יי		•	» ¢	. ر		φ.	7	w.	4	86.5	σ		:	98.5		92.3	90.8	93.2	92.2	88.7	94.8	MCV	1
15.1	14.6	_	12.4	_	_	_	13.	_	<u>.</u>				- :	1	12.	12.	14.	13.	13.	11.		1					<u>۔</u>	17.	12.	16.				; :	• •		:	1	4	-	•		16.4	•	13.5	13.2		13.2	13.5	15.2		•	•		16.1	15.4	HGB	: }
. 46	.46	.79			1.48		٠			٠.	;	7.7	. 74							. 7				n c	9 0	ς,	0	9	. 48	. 53	2.08	<b>&gt;</b> -			n .					0	. 7	-	1.48	w	0.00	3.48	7.03	2.03	2.11	1.15	2.51	2.78	2.50	7.43	7.82	5.42	TSH	•

1555	1552	1550	1542	1541	1524	1519	0.00		200	1007	ο,	998	ø	8	Œ		۰ ،	,,,	071	0 10	2 7 0	960	959	9 5	944	942	939	938	934	932	931	926	920	914	911	9 9	9 0	9 0	0 0	2 C	) ( ) ) )	0 0	D C	0 C		2 4	2	B 0		٠ . د د				831	830	о Ј Л	PID	
2	_		2	2	, ,_			٠.	<b>.</b>	<b>,_</b> _	2	2	۲3	~	<b>,</b> -	٠,	د د	<b>.</b> .	<b>-</b>	<b>.</b>	_	~	~	2	-	2	-	2	2	2	· -	۰ ۷	, <b>p</b> -	• •	, r	<b>.</b>	<b>.</b> •	٠,	<u> </u>	·	<b>&gt;</b> :	<b>.</b> ,	۰,	٠,	<b>J</b> F	، د	٠,	<b>-</b> ,	٠,	<b>&gt;</b> 1	<u>.</u> ,	<b></b> - 1	<b>&gt;</b>		<b>,</b>	2	Xas	
51	64	51	41	. 0	\ U	n (	n 4	<b>.</b>	2	<u>ھ</u>	60	46	47	. L.	2 6	<b>.</b>	<u>.</u>	A :	5	62	66	42	46	<u>۵</u>	69	79	48	61	69	69	6	- A	. 0	י י	7 £	- (	n C	9 6	<u>.</u>	71	5	7 6	5 G		7 (	л· (	÷.	6 4	6 9	60	60	61	GO.	<u>ت</u>	ម ម	52	AGE	
æ	5000	-	٠.		• •	J C	p.	6400	S	Ğ	6300	ū	-		0000		6600	5	7	9	ᅀ	9	7	4	2	2	4	5	9	2	2 9	0000	, ,		5 6	5 6	ວິ	2	ö	5400	8300	7500	10600		^ .	-					_				6600	6200	. MBC	•
ຕ	2500	9	3	7 6	,	- t	2,	96	89	99999	02	4275	7	5 7	יט		_	~	w	~	w	_	_	_	•••		_					7 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6						_	· ^		~	••	•		σ.	•		- 1	$\sim$	-	$\overline{}$		~	~		2914	PHN	:
		4666				э,			99999	999		-		,	00000	0	0	0	0	44	0	0	0	999	99999						,	00000		, O (	<b>.</b>	0	æ æ	0	0	0	0	75	0	81	0	55	0	0	0	0	0	88	0	63	99999	0	BAND	;
		777		ب م د	֓֞֜֝֝֜֝֝֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֡֝֝֓֓֓֓֓֡֝֝֓֡֓֡֝֡֓֡֓֡֝֡֓֡֓֡֡֝֡֓֡֡֡֝֡֓֡֓֡֝֡֓֡֡֡֡֡֝֡֡֡֡֡֝֜֝֡֡֡֝֜֝֡֡֡֝֜֝֡֡֡֝	ا د	120	. 17:	7.5	99	2898	2	3 4	3 1	9	~	7	8	39	=	2	2	۵	3	~	~			• ••		= :	2301		≃.	ጓ .		~		•	91	98	27	66	26	8	=	0	4	97	05	6	89	69	•	1584	2790	HAMAT	
7 2 2 4		200	0	~ (	<b>a</b>	_	~	σ.	2	999			, ,	,	999	~	<b>س</b>	~	<b>,</b>		4	. ~		999	ه ا		) t					204									83	~ 1				~	•	•	~			•	m	•	264	_	MONO.	2
	٥ - د د د د	,	0 1	2	0	246	48	64	œ	٠	, <u>-</u>			ت ح	ø	w	9	N	9	88	94		٠.	99999	)							272	-										212	0	0	•	10	216	•	. ~	_				264		5	
,	-	,	99999	0	0	164	0	0	190	46666		, i	7 .	0	99999	0	6	3 2	٩	4	•	• •	•	. ע ע	2 4 0	, ,		, ,	۰ م	7	73	99999	Q,		_	9		_		•	. co		0	0	9		0		w		0			۰ تـ	66	0	3	HASO
	21	-	30:	235	261	181	223	145		, v	2 -		ν.	0	ø	0	۵															263															193	256	202	248	241	214	213	2 6	230	255	ţ	P1.T
	41.	٠	12.	42.	39.	47.	46.	48.	4				4	ა 8.	99.	45.	41.								3 6		 	4 9	9 1	٠.	ა 6	44	ب 5	39.	34.	39.	41.	46.	47.	60.	ê	سا سا •	ů	41.	36.	36.	•	•						•	200	•	:	HCT
	5.31	u	~	5	ح.	ç	<u>ب</u>	5	٠.	n 4		٠.	_	ج.	9.	٠.	۵.	٠.				•	, . , .	•	•	•		•	4.19	•	•	4.88	4.09	4.33	4.05	•	•	•	•	•	 	•	•	٠.	4.07	3.83	:	. 4	·	. 4	Ė	•		. :		4.54	,	RBC
	77.	•	9.	8	7.	91.7	9.	•		n :	٠.	79.4		82.7	999.9	٠			, ,	26.1	3 (		• :	٠:	- :	-:		-	•	~	:	91.0	٠.	$\overline{\cdot}$		•	•	•	•	•		٠	•	•	•	•	•		٠		•					86.7	:	нсч
	3 14.0	11.	12.	15.	13.	16.	16.	: :	•	•	•	13.0				Ü				л .											w	15.9	N	w	2		•	. 0	۰٥	٠.	ء د	•	3 6	ع د												13.4		HGB
	Ġ	u		٠.		2.45	٠.	3 6	1		999.99				999.99					1 07	30	2.71	2.14	2.28	2.45	•	87.41	2.17	1.16	2.84	2.76	. 99	1.45	:-	1.12	٠.	1. / 5	•		1	1 77		0.00	J L				1	חכ			200	1 29	ا بر د م د بر	1.61	2.20	,	TSH

22	22	N	. N	N	. ~	2	-	-	-	-	-	-	-		-	-	-	-	_		-	_		-	⊷ •	_		-	2 1				-	-	-	-	1		) N	2	21	21	21	21	<u>,</u>	<u></u>	<u>,</u>	5	<u>.</u>	<u></u> 5		7
16	5	<u>.</u>	10	60	07	90	97	96	95	88	79	76	74	72	71	67	60	58	56	5	52	50	49	8	5	4		2 ,	9 0	ם מ	7 6		30	26	19	17	5	2 5	<u>.</u>	8	07	90	04	02	77	72	67	64	59	5 5 6		D
																																																				ω
2		~	) N	<b>N</b>	سر ر	. بـ	N	N	N					~ ~	2	-	2	N	-	-	-	-	<b>~</b> 1	<b>-</b>	<b>-</b> ,	<b>-</b>	٠.	، س	N 1	٠,	- r	) K	N	2	N	2	-	٠ ,	<b>پ</b> د	٠, ـ	~	-	N	. م	<b>~</b>	-	<b>~</b> 1	<b>.</b>	<b>.</b>	<b>2</b>		×
-	7	•	. 4	م	۵.	~	4	2	6	4	-	5	4	U	_	5	^	6	2	4	S	رب در	<u>.</u>	æ :	<b>.</b>	A 4		٠.	<b>.</b>	<u>.</u>	<u>.</u>	•		4	58	20	40	8 4	<u> </u>	9 05	6	4	6	50	د ا	۵.	<u>~</u>	_ ـ	. حي	<u> </u>		AGE
_		-	٠.			~	<b>—</b>	ω		<b>پ</b>	· w	٠		~	~	_	_	_	~	_	_		Ψ.		_	~ .	٠,	٠. ،	U. <b>-</b>					_	_	_	_	•	,, ,		٠.	_	_		٠.			<b>G</b> 1		<b>9</b> 4		N
_				,										_						_						9				_						_	<u>.</u>	<u></u>			_	_				_			,			
160	60	6	2 6	20	4	80	10	60	-	80	6	<u>ا</u>	50	20	90	30	80	0	20	00	0	80	40	90	00	9 6	<u> </u>	3	0 0	<u>-</u>	7 C	9	80	8	80	00	40	0 0	3 6	90	10	20	99	30	70	0	50	<u>ا</u> س	<b>~</b> 0	420 010	•	МВС
											ō														,	٥																	9			0	0	0	0	ŏŏ		Ō
_		0	٠.			0			m	-	. ~	0	9	-	•	8	7	N	9	·	8	0	<b>UT</b> 1	w	9	9	Э, С	ו תנ	മ			ı U	: 40	9	7	8	9	20	၁ ပ	. ~	4	0	9	457	0		G,	7	ø.	138	•	P
6	0	•	۰ د	) N	<u> </u>	0	0	0	9	ŏ	6	ō	0	9	8	ລັ	8	2	ō	ō 9	6	ō	<b>N</b>	ō ;	0	٠ د	л	9 (	9	<b>&gt;</b>	5 6	5 0	N	9	9	ō	φ.	in i	ي د	9	w	4	9 9	0	اسا	-	0	ທ	7	4 6		Ï
	999	)	99	999		99	ō	99					99	99	ļ					99			;	99		9		•	9	٥	-				99			9		9	1	ผ	99		;	999	99		999			BA
0						99				0	84		99		0	0	0			99			0	99	0	9 0	<b>-</b>		9 0		0	9 0	0	84	99			9 0		9 9		24	99		0	99			99	0 2	•	AND
<u> </u>	. 2		2 2	2 %	N	. 2	2	<u></u>	-	20	w	<u>, , .</u>	۸,	2	2	2	2	<u>س</u>	_	<b>⊷</b>	-		<u>ب</u>	2	2	999	_ :	2	<b></b>		<u>.</u>			2	1	26	ω	N :	٠ د د		<b>A</b>		999	3	2		<u>_</u>	<u>س</u>	۵.	2 2 8 4	,	IXI
-	•				•	. 0	_	•	N	œ	-		•	8	6	N	8	~	J	8	w	8	<b>0</b> :	_	8,	9 .	_ (	s.	70	<b>-</b> •	~ ~	•		8	ø	•	S	5	צפ	<b>5</b> 5	·	0	9	S	9		0	· سا	vo	178 128	1	YHPH
	ۍ .					,	,	~					۵							2				u		99			٠ 4					•									99									MO
100	934		0	204	•	æ	9	w	U	0	168	-	9	•	-	8	9	ð	۵	œ	S	9	7	، ب	N	0 1		•	o v	00	<b>&gt;</b> 0	١ 4	. •	9	w	4	2	20		- 0	•	~	9	150	Q		450	-	ō	84 101		ONO
	_					_	,		,			,				99				_			<b></b> ,	_		99			۵.						2								99								-	
سا	. 6	· a	1 N	<b>,</b> ,_	• 6	334	9	9	w	U	504	v	, ,	372	S	9	390	8	۵,	440	0	ø	316	9	-	999	2 6	9	486	5 6		١.	1 2	504	w	8	8	525	>			784	ø		174			Ü	6	707		EOS
•	. ~		. v	,	<i>,</i>						99	,	9	99	,	99	Ĭ	•		99		99			,	99	_ `	_ `	_ ,	- ` 0			-	_		_		9 9			_	_	99	_	_	99	_		99	7 99		
1	77		y	35	· œ	سَ د	9	Ñ	,		99	37	99	99	)	99		16	_	99	0	99	9		, ,	9		5	38	9	ہ م		7		34	8		99			36		99	66	7	99			ō	9	)	BASO
a		٥.			<u>م</u> د	٠.,	7 2			0	,		9 2		0		0 3		_	_		9	·	-	_ 	9 2		~ ·	۰ م د د					. w	N	0 2	- N	9 6				N	5	2	 N	_	0 2	ب 2	9	9 9 9	•	7
2	4		2 6	-	9	0.2	16	94	8	61	5	54	6	~	4	12	0	96	17	90	0	96	80	5 2	37	99	~ ·	16	78	, ć	2 t	2 4	77	62	69	w	2	- (	лС	> ~	7	ະ	99	83	94	99	49	4	18	123	•	LI
5 / .	6										51					-	_	7	_	49.	~	8		ū,		ō		_ ;		,	S o	·		7	40.	ผ	Ö	36.	ט ס	2 2		ھ		ເກ	ō	8	0	0		40.		<u>=</u>
Ý	<b>.</b>	٠ د	0	· œ			9	N	0	7	<b>,</b> _		Δ.		œ	CT.	8	0	œ ~	<u>-</u>	<b>س</b>	œ	<b>س</b> ،	•	N ·	9	л (	0	٠ م 	•	o	<b>3</b> ~	. ~	9	9	<b>-</b>	о С	<b>-</b>	. r	. ~	9	UT.		_	•	0	8	0	ب د .	<b>→</b> 60	,	H
					2	5	. 2	-		-	2		ü	5		-	. 2		<u>.</u>	. 7	. 9		0	6	_		_		5		ם ת	n -		<u>.</u> پ	. 7	7	7		ے م	- œ	. 2		. 9	. 9		-	2		.4	5.5		RBO
a			_			-		_																	,	9													,_				9							0.6		Ö
9 2 .	6					86.				87.	82.	93.	85.	88.	87.	88.	87.	87.	89.	4	89.	•	87	<b>,</b>	94	9	82	87.	93.	7 t	<b>.</b>	<b>-</b>	• 6	0	86.	9	7	86.	ם ע	9 0	0	~	9	N	9	N	85.	S	9	93.	•	N N
0	9			> ~			0	۵	. <b></b>	2	0	5	. 5	. 2	9	_	۵	4	7 1	8 -	_	<b>○</b>	2	æ <b>→</b>	7 1	9,		<u>.</u>		<b>~</b> •	<b>⊃</b>	۸ <i>د</i>	, <sub>1</sub> ,		0	5 -	9 1	6 ·	→ ν ⊢	# #	-		9	-	6 1	6 1	æ :	<u>~</u>	<b></b>	20		<
				, c		4	•			5	7	U	. 6	À	س	5	4	2	4.	•	•	•	2	•			4		-				•	٠	•	•	•			•	٠		٠	7.0	•	•		•	•	4.9		HGB
•				. •						. •	- •1	س.			<del>س</del>		_	•	_					_		99	•		٠. ٠	- •	•	- •		_			_				_		95		•	_	_	_	_		-	-
-	٠.			۲.		٠.	2.	6		1.		٠.		. س	37.	-	-	:					<b>N</b>				2 :	-	<u>ب</u>			•	•	٠.			•	-:		- ?	2	-	99.	٠	-	Ξ.	-		-			78
	۔ ـ		, c	•	o	v	ď	-	0	•	, N	9	v œ	•	. 9	•	9	-	4	~	-	7	<b>~</b> 3	S.	Φ,	9		N :	- 4	. د	30 C	ou		0	9	Ç	œ	Ţ٠,	P 0	7	س ،	·	9	9	~	9	8	_	7	00	١.	=

2548	2277	2274	2273	2271	2269	2261	2257	2256	2255	2254	2251	2250	2247	2245	2242	2239	2236	2235	2234	2232	2231	2230	2229	2228	2227	2226	2225	2224	2220	2217		PID
<b>ب</b>	2	<b>,_</b>	<b>-</b>	_	_	_		N	2	2	N	<b></b> -	~	<b></b>		N	<b>-</b> -	-	-	•••	N	N	2	8	~	8	N	N	2	2		8EX
39	ô	39	39	39	0	65	47	<u>а</u>	0	4	5	50	48	0	40	43	51	47	52	42	41	52	58	8	4	41	47	71	65	61		AGE
7300	8900	7500	7200	6000	5800	5700	3400	6900	7100	5600	7400	7900	7900	8000	6100	7000	8600	8300	8800	12700	6300	6900	7800	13300	9400	7300	7500	7600	7100	6600		нас
4891	6319	3680	4536	3420	3480	2679	1734	3860	4331	2688	4440	5214	5060	5040	4392	4130	5762	4399	5104	8763	4788	3933	4212	8510	4425	4672	5550	3720	3337	3498		PHN
0	0	99999		99999	0	0	99999	99999	0	56	0	0	0	0	0	0	0	83	88	0	63	138	78	99999	0	0	0	809	0	132		BAND
1533	1869	3680	2232	2100	1624	2280	1122	2550	1988	1960	1776	1896	1900	2240	1159	2030	1978	2573	2112	3048	1197	2415	2886	3720	2625	2190	1425	2740	2627	2376		нана
438	356	99999	144	2160	464	570	306	1932	568	. 336	296	79	. 4977	480	122	350	258	498	440	762	63		312	8911	225	219	300	3496	710	330	,	HONO
292	267	1125	912	720	174	171	99999	966	213	504	814	632	2528	160	427	420	430	249	88	127	126	345	312	5320	225	73	225	4636	426	198		. Eos
146	. 89	66666	72	66666	5		66666	483		56	74	79	66	: :		70	172	166	. 88			69		1729				66666	)	. 6	:	BASO
248	198	1/2	707	299	233	105	220	337	170	3 2 5	100	266	220	0.82	239	305	287	215	314	201	366	312	259	334	320	232	288	513	230	7 6 7	•	PLT
45.3	40.5	- 40 - 40 - 40	90./	47.1			99.9			39.7		97.2	29.7	41.5	4.0	37.6	٠	•	44.8	9.5		44.2	43.0	39.8	•	•			41.0	•		HCT
5.09	•			, ,			5.32	3.27				5.65	3.74	· · · ·		9.30		4. / 3		2.0			4.86	4.00		9.90	4.00	10.1	. 0		3	RBC
89.0	24.0	10	0 0			•		Ü	ن		•		٠,٠	٠			į	2 .	ن د	94.2	20.	7.0	ď	•	20.0	٠	7,7	2.4		•	3	HCV
15./	, ,			17.0			-	•	•	13.1																•	•	•	•			1100
		٠ ٠ ٠	л с л г	 	- 6	) k	, v , v , v			•	10.0	•		• •			3 d 3 d 3 d			7 . 0 7 0		1.07	1 07	٠.							J	TSH

88888888 111117777788888897777777888889777777888889777777	910 5 7
N - 1 8 1 8 1 8 1 9 1 9 1 9 1 9 1 9 1 9 1 9	2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
<b>☆ で り 4 4 6 4 4 6 7 7 7 7 7 7 7 7 7 7 7 7 7 7</b>	7 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
	7 8 6 7
200000000000000000000000000000000000000	
$\begin{array}{c} 555\\ 555\\ 556\\ 556\\ 556\\ 556\\ 556\\ 556$	10 10 10 10 10 10 10 10 10 10 10 10 10 1
	999
6 8 1 5 3 9 9 0 1 3 0 9 9 1 7 2 2 4 4 7 9 4 6 0 2 6 5 2 0 6 9 8 9 0 5 0 7 8 9 4 7 6 8 9 8 9 6 6 8 9 1 5 0 5 0 5 0 5 0 5 0 5 0 5 0 5 0 5 0 5	115753
9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9	HONO 576 130 574 420
99999999999999999999999999999999999999	30 U G 40
99999999999999999999999999999999999999	40
22222222222222222222222222222222222222	72112
	- 4400H
	7 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5
988998899898989899899899998998999988997899899	× O →
11111111111111111111111111111111111111	115.1
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	1 3 8 1
122 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	
	🗩
\$\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\	
	×484
	8. 0 7. 0 11. 1

2	2	2	N 1		_ :		-:		-		-	·		<u></u>	n.U	5	5	5 5	5 2	ဖ	9	۰ ب	ي م	စ္	9	9	9	9	ب	9 4	9 9	91	800	8 8	86	ν φ φ φ	8 4	84	84	30 C	. œ	83	834	. B	, <del>T</del>	
	10	0	0	5	3	7	7	. 0	5	5	5	56	5	2	٠ ا	19	43	9 0	ב ב	98	80	71	<i>y</i> 0	ເລ	0	59	51.6	5 6	8	2	50	-	0, 1	- د	Ф.	<b>7</b> U	'n	^	اسا		ο Φ	G	4	<i>د</i> د	. 0	
u	0	<b>~</b>	ດ ເ	∾ .	-		٠.			_	_																																		ຜ	
2	_	~	-	-	~	<b>.</b> .	<u>-</u> 1	<b>5</b> F	- ~	, N	مبو	2	<b>-</b> 1	<b>ب</b>	<b>ی</b> د	-	2	- *	, r	1	2	-		<b>س</b> د	. ~	20	N 1	<b>5</b> –	. ~	~ .	-			•			•						<b></b> +		×	
																													_						~1	m 0			σ.	<b>.</b>			. 6. (	on 12	ă.	
4	υ	6	۵	Ç	۵	Δ.	۵.	۵,	A A	4	ه.	5	6	٠.	5 £		60	<u>د</u> ه	> 0	4	2	52	9 5	2 6	2 3	9	2	804	200	70	200	22	5	- 2	2	Ø. F	- 0	6	6	2	лΝ	-	61	N -	1 [7]	
6	-	0	G	_	_	5	7	51 1	۰,			_	•	••	-															•							_	_	_						_	
~	~	10	10	8	6	5	^	٠,	ла	<u>ں</u> ہ	0	_	ڃ	6	6 5	3 55	5	5 5	9 0	N ~	0 2	8 2	<u>د</u> د	9 G	16	0,	08	71	2 6	87	740	8	=	2 6	<u></u>	8 2	3 5	5	Ö	9	7 2	5	6400	200	3 5	
Š	50	20	20	20	20	30	6	50	200	2 6	30	2	9	8	$\tilde{g}$	000	2	00			0	00	00	2 2	30	8	8	000	30	0	0 0	9 9	5	5 6	0	5 6	3 2	5	ŏ	5	5 2	5 5	400	ŏ ō	ה כ	
Ç	0	0	0	0	0	0	_	٠.		-	-		_																																	
																<b>.</b>	ددا	<b>N</b>	<b>a</b> (	~ ~	ى د	ر.	2	<b>5</b> 1	س د	u	J.	، م	م د	ح.	9 4		2	N U	i w	6 8	- 6	2 22	ω In	28	ب د د		352		7 T	
٥	2	61	48	45	2	25	2	2	2 6	ם מ	, 6	Ξ:	89	7	8	2 6	1	S	-	٠,٧	99	88	70	96	5 8 7	3 5	12	47	2	8	9	2 8	Ξ.	96	. 65	4		9	40	9	9 1	3 K	3520	8	- Z	
7	50	64	88	92	54	4	8	8	9	3 6	7 0	, 6	5	2	Ö	5 c	Ö	8	- ,	n e	• •	8	0	w	D 0	, 0	0	<b></b> (	,, ,,	. ~	- '	_	•		ب. و	Ξ,	- ·	-	ຶ່ນ	•		– a	õ	_		
	,	v	· vo				9						9	9	ø						9				2	3			ž	9	3	<u>~</u>			9	_ :	٠	<b>.</b>	9		9 4	٥			₽	
7	3	99	99		6		99						9	9	9	2 _		_	89	0 6	99	9 2	0	0	2 4	30	0	0	<b>7</b>	9	9	9	-	0 0	ĕ	8	<u>ت</u> و	5 č	9	0	نو	ے م	0	0	ם פ	
	ء د	υ.	س د	. 2		٠,	,	۵	~	<b>س</b> و	J,	ے د	, _	=	~	2 -		2	20	N 1	ب س د	2 2	1	25	- 5	٥ د د	22	23	5	3 19	9	2 6	2	2	- 5	7	<u> </u>	ۆ ۆ	5 6	55	Ξ	_ 0	200	5	, Y M P H 2829	
Ġ	7 0	7 2	3 6	78	9	17	80	57	26	2	5	"	6	4	86	= 3	č	=	43	Ü	y 4	9	50	8	10	74	6	43	96	2 2	99	70	-	4	ا ا	Ö	8	5 }	- 6	9	8	G C	5 0	•	4РН Н 329	
3	5 6	0	0	, œ	α .	w	4	Մ	ω '	9	2, 1	<b>.</b>	, 0	, ω	0	ω (		_				5									9										LT.		<b>-</b> N		u H O	
		٥	ه ه	. ~		٠,	. 2	2	2	<b>.</b>	٠.	بر بر ع ب	ی .	س .	7	٠.	- 6	<u> </u>	~	2	<u> </u>	٠ د د	18	17	25	٦ <del>١</del>	. 6	14		27	99	<u>س</u> ۵	3 6	10	40			30.							~ 7	
- 6	2	2	2 2	1 6	9 6	6	64	25	70	74	72	5 -	- 0	3 8	0	8	πü	. 6	9	0	8 4	٥	0	œ	N	3 K	0	12	0.	~ 0	. 6	<i>-</i>	3 55	<b>.</b>	<b>5</b> 6		-	٠,	-	,	,	···	7 6 0			
																				!	2	9 .					. 9	;	<b>,</b>	ب م	· 6	w r	ىيا م	,	. n	, ,	æ	<b>~</b> (	ب ب	·	Ç	9	<u>ب</u>		2 8	
	2	7 6	9 U	, ,	, ,	ب د د	. ב	2 2	16	26	-	5	ä	56	8	5	- 0	. 6	3	2	16	0 0	\ N	78	55 5	3 F	99	71	90	מ ה	7 9	25	2 0	0	2 2	6	ພ	ö :	4	4	<u>~</u>	9	0 4	-	)7 B	ı
	Ú, C	n d	- 0	, ,	ی د	0			2	-	Φ.	•		ם עם		٠. ٠		-	-	•		ייס	5		,	9				~	-		_									<u>, , , , , , , , , , , , , , , , , , , </u>			BA	!
	9			0	,	0	7				_		_				_		.=	_		À 1	•		,	9 5	5 6	; ~		99			0 2		_ •	, œ	9	6	UT C	, U				9	7.0	
	9 :	7 (	3 5	0	٠,	٥ د	, 4	75	0	74	18	<u>د</u> ۵	) v	9	6	8		۾ د	9	Š	0	Ď 4	ົທ	0	0	9 1	ა c	<b>, ,</b>	0	ωα	w	5, 1	0 N		- L	3 @	8	<u>.</u>	Ψ.		~	_		-	<u>0</u> 0	•
																				_			J N		N			. ر	-	- ~	ง	٠,	ر د د	-			N	-	-		2	N	2 2	2 22		•
	<b>u</b> (	- (	بر 10	2 :	2 :	2 +	- :	1 2	23	24	28	18	2 -	- 6	20	5	2	3 6	4	4	6	Ü	5 H	28	1	<u>ب</u> ج	3 6	72	63	u u	52	61	ה ה	. 2	9	2 2	25	77	-	- 2	2	3	تا هـ	- 0	183 3	3
		_		-		-	л •			_	-	_	-																													_				
	37	4	ω , 5	5	5	د د. د د	3 (	7 4	2	2	39	4	5	5 5	3 8	9	5		<u>.</u>	0	8	<u>ب</u>	л C	, N	9.	.7:	<u>ہ</u> د	• -	7.	5	. 57		- :		<u>:</u>	- :		Ξ	<u></u>		Ξ,		2		9.8	1
	•		•				•	•	•	-	٠.	ī.,						T. L.		Ф	σ.	<b>~</b> ,	- 4	•	Q	<b>,</b>	<b>~</b> ~	oω	•		-	_		. •					-							-
		_	_	LT .		. ب	"	л £	۵.	. თ	۵	4	. ب	۵,	7 A	4	Ç,	<u>ب</u> م	י י	ij	•	5			•	•		- ω	•	-:		-	- :	•			-	•	•		·		::			7 71
		. 7	<u>.</u>	٠.	. ,	9	0	ه ب	٠.	حة ب	<u>.</u>	Ö	@	2	ھ ب	6	ر د مر	9 0		, <u>, ,</u>	71	07	2 6	201	2	42	£ 6	ა <u>ი</u>	6	8	2 8	<u></u>	2	: 2:	<u>ت</u>	<u>ت</u> ت	9	4	6	-	1 12	æ	N C	<b>4</b> R	200	3
	w	0		w ·	•	٠, ı	_	٠,		<i>,</i> –	٠.																																	~ ~		
	7	<b>&amp;</b>	8	<b>&amp;</b>	ဖ	9	۰	<b></b> c		, ,	0	9	9	æ :	2 0	8	28	ω u	n C	79	8	86	8 6	200	88	8	œ ۱ ت	200	8 ==	85	ے د	2	7	7 -	5	7 .	3 2	6	Ξ	<u>ت</u> ة	5 6	៊ុ	91.	<u>.</u>	9.0	Z O
	<b>ب</b>	8	•	٠.	5	0	•					:	=	· :						•			 N .		; <b>.</b>		-:		٠,	9	_ 0	۰.6	<u>.</u>	• 0	œ	<b>~</b> ⊢	• -	0	4	7	<b>4</b> 0	. 0	-	N 1	9	<
																						-				-	-										٠.	· i	•	_ ;	. i	3 (0)	un e	<b>&amp;</b> u	. u	<b></b>
	12	15	12	17	16	12	9	5	- E	2 2							ū	-	,	n iu	٠.	٠.	5	ء د	۳.		- 9	. ·		. u		. ω	ω :		•	:	- :	·							ວ ພ່	а С
	. 6		٠.		. 9	. 9	5	5	۲.	٠.	· •	ີ່ເກ	<u>.</u>	-3	6	س	8	u ۰	0 4	ں د	, 0	7	<b></b> (	71 K	<b>,</b> ~		•	ur o	۰ ٦	0	o	, 7		. w	~	•	-	٠	_	<u>.</u>			-		ا ما ه	
									J.						<b>.</b> .			<b>,</b>				10					. س	, ·	, ,	-	_ `	- د		-	-	N		-	<u>سر</u> ،	9		ب د	٠.	♣.	. 2	н
	-	:	:					•	•	- ^	•	· <u>-</u>	•	:	• •	_ :-	•	•		٠.					•	•			٠.				-							50			-	4	00 75	C)
	60	9 8	70	49	49	50	2	80	۳ ر د	2 5	3 6	<b>-</b>	4	u	0	-	0	Φ,	В (	٦ ٢	. س	w	٠,	U. C			7	55 4	۵ س	. 0	<b>B</b> 0															
		_									_	-	-			-	_	-	☱.		_ =		1	5 5		, 5	9	10	۷ م	9	9	<b>5</b> 0	8	56	2 2	9	9	ي ه	9	9	Ö	ی ه	90	9:	9.6	CA
			9	9		9.	•			_ :				Ξ,		 _ ∟					. 0	. &	. 9	. :	٠.	, <b>.</b>	•	::	ه ه	Ö	6	٠,	-	بر در	, 20	7	œ 4	-	4 @	9	0	9 4		9	9 0	۲
	œ																																											444		ВH
	<b>L</b>		س ,	_	س.	2	2	4	ب ب		ب ب	. u	-	س •	w		٠, ٠	•	ٔ	•	٠.	ω.	2.	ω:	ے د	. س	•	-			-	- :			٠,					م		7 .	. <u> </u>			SO
			٠.			. •	Ġ	6	9		٠,	ے ب	6	·	2	<b>~</b>	ب د	-	9	<b>,</b>	ے ب	9	6	w	<b>20</b> U	ת מ		0 1	N C	, <sub>N</sub>		_ ~	. –													***
									_						۵.	ء ب	_	ه.	_	۵.	• •	. س	_	u i		ه د	. س	-	ہ ب	س د	<u>س</u> ،	٠,	ب ب	<b></b> .	٠.	w	ω <u>.</u>	ب ب	ب د	قِ ر		٠.	<b>ب</b> د	•	3.0 8.0	81
	٠	ء .	٠	۔	٠.	. w		-	_	_ :									5		 			6		-	٠.	-	•	o	0		o o	<b>9</b> F	ع د	8	UI	<b></b> •	۰ -	9	0	φ ,	၁ ဖ			,
																																					_	_	_					• • •		
						٠	•	-	9	9	9	9 4	9	9 9	99	<u>.</u>	9 4	99	99	<u>۔</u>	99	9 9	12	99	99	9 9	99	_	9 '	ວິເກ	9	ğ <u>.</u>	, <u>9</u>	5	٠,	9	9	Ó٠	۰ م	o t	9	9	9	9	00	R d
	•		•			. •		. ~	.:								٠.		. 9	٠.	 •		· -	. 9		٠,		•	. 9	٠ ت	•	ن ت	ģ	ω i	- م	0	9	o i	ب 0	·	9	9	9 9	, 9	9 2	, [
	-	- 4	n .	a u		, v	, 4	, ~	v	~	~ '	4	-		_																															

22134 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 2214 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 2214 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22144 22	
	0 1 2 2 2 2 2 1 1 X
3.7.4.4.4.7.8.4.5.7.4.5.4.5.4.6.4.6.4.7.4.6.4.6.6.7.4.4.4.4.4.4.4.4	7 9 9 9 9 9 9 9 9 9 9 9 9
7500 7500 7500 7500 6100 6100 6100 6500 7700 7700 8700 8700 8700 8700 8700 8	594697701
5475 5475 5475 5475 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405 5405	2922657945 424646465
9999 9999 1138 9999 0 0 0 186 65 65 65 65 65 65 65 65 65 65 65 65 65	BAND 71 0 114 0 9999 9999
11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750 11750	7
9 1 4 5 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7	<b>70 - 90 0 0 0 0 − 2</b>
	1100 1110 1171 131 138 732
104 104 104 105 106 106 107 107 107 107 107 107 107 107 107 107	BASO 71 0 171 0 46 9999
22 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	700mmarueru
	#4400000
AAA U U A U A A A U U A A A U U A A A A	20022200 2002220 2002220
98888897888878993334 98888889788888888887893334 9888118884508464119434 9888118845564811787888888878917878	84.5 84.5 84.5 84.5 87.7
, , , , , , , , , , , , , , , , , , , ,	113 114 113 114 114 114 114
1.1.2.1.2.1.2.1.2.1.2.1.2.1.2.1.2.1.2.1	TSH 1.30 2.75 1.31 1.96 1.96 2.00 1.77
10000000000000000000000000000000000000	10.61 9.65 9.20 9.14 9.4
	PHOS 3.6 4.4 3.4 3.7 2.9
100	88.769.4479

~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
PID 22447 22548 22550 22550 22550 22560 22660 22660 2271 2271
8 8001000000000000000000000000000000000
AGE 550 AGE 55
WBC 6200 7700 9999 11800 4900 8600 5900 5900 6500 6200 6200 6200 7200 8800 7100
PHN 2600 43600 43696 9999 9676 5676 5005 7622 7622 105698
BAND 9999 977 9999 09999 177 9999 1130 1130 103 103 103 143
LYHPH 2860 2079 9999 11770 11568 2064 2360 9999 3094 1105 1105 11734 11734 2574
99 30 30 30 30 30 30 30 30 30 30 30 30 30
9999 9999 108 108 108 109 109 109 109 109 109 109 109 109 109
9999 9999 9999 0 9999 177 177 177 9999 9999
2011 2011 2011 2011 2011 2011 2011 2011
444444 6684 6684 6684 6684 6684 6684 66
55.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5
999.9 82.7 882.9 999.9 85.2 85.2 85.4 91.9 91.9 91.9 91.3
114.0 114.0 114.0 114.0 114.0 114.0 114.0 115.0 115.0 115.0
731 1.10 1.10 9.11 4.20 1.00 1.00 1.53 1.93 1.93 1.93 1.93 1.93
9.91 9.32 9.44 9.44 9.47 9.47 9.47 9.47 9.47
PH 31.00 3.00 4.00 4.00 4.00 4.00 4.00 4.00 4
PRI 110.5 110.5 110.5 110.5 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 110.6 11

88 88 88 88 8 200	PID 33 55
100001100100100100100000000000000000000	8EX
5544444455555556465574775455456555445545545445665 05667777777777777777777777777777777	PGE 433
1 19 9 11 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	667876
νος της της της της της της της της της τη	8404684
62555666666666666666666666666666666666	
	9 M
	2
2422445246533355513323433342551335444222343333 685557019220775295513322433555555555555555555555555555555	00 H 0 N N K
	<b>→ =</b>
	2
213544044475273322331602111602132324	
	# B D D
22 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	: 6 U B B B B B
\$\$\$\$\$\$\$\$\$\$\$\$\$\$\$\$\$\$\$\$\$\$\$\$\$\$\$\$\$\$\$\$\$\$\$\$\$\$	• • • • •
A WAAAD WAAAD WAAA W N W WAAA W A A A W W W W W W W W	<b>840446</b>
~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~	,556021
798909888999988899999999988899999999988999999	0040400
	# # # # # # # # # # # # # # # # # # #
40888888888888888888888888888888888888	
DAACK C AC FC D OUC C CC COTAL FOOD COACCA A	00~0~0
0145560001004040000000000000000000000000	400004 V HUU4444
	2299792
	НВSA 9. 9. 0.
0000 000000000000000000000000000000000	999 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~	N 0 7 51 W 7 9
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	4000000

83310 83310 83320 83333 8333 8333 8333 8340 8333 8340 8341 9341 9341 9341 9341 9341 9341 9341 9	7 55 50
<b>ユュルトコエルコエスのようはしょくにんのかしょうことにこれによくにしこうにいいっぱいのいしょうのうしょうのうしょうのうしょうのうしょうのうしょうのうしょうのうしょ</b>	×
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	4 2 2 2 3 4 4 7
11	5.6 5.6 7.9
442.0 442.0 554.0 564.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 577.0 57	
99 5 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7	- A 2 1 3
34 2 2 9 3 3 1 1 1 2 4 2 2 2 2 3 3 6 5 6 5 6 7 6 7 6 7 6 7 7 7 7 7 7 7 7 7	4 3 6 K
11	100 100 100 100 100 100 100 100 100 100
3723 - 0 - 0 - 0 - 0 - 0 - 0 - 0 - 0 - 0 -	2003
	# 0000 ;
12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000 12000	PUAT 1183 2249
00100000000000000000000000000000000000	<b>ω</b> υσου
AAUU 9 AAU AAAAAAAAAAAAAAAAAAAAAAAAAAAA	សមសភាព
999110000000000000000000000000000000000	0000
	ω N ω Δ ω
99.196 99.197 1.17 2.487 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181 1.181	<b>⇔</b> ⊌ 9
11000000000000000000000000000000000000	TB12 364. 428. 504.
	HBSA 0. 0.
90 900 900 900 900 900 900 900 900 900	98A 1.3 99.9
9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9	HA1C 99.9 99.9 99.9

$\begin{array}{c} 2 & 2 & 2 & 2 & 2 & 2 & 2 & 2 & 2 & 2 $	
8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8	
9957684	
野はブビビはようましょいらいちちほどの日はみのもちもいちょりりほど19861459201629に	
999674.00.00.00.00.00.00.00.00.00.00.00.00.00	
99000049115374100840550620240086900690008	
••••••••••••••••••••••••••••••••••••••	
9921126333333333333333333333333333333333	
20 1 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	
8401840194019401840184018401840194019401940194019401940199	
99 1 0 1 1 0 0 0 0 1 1 1 0 0 1 1 1 1 1 1	
9232492112231231332333233222222222222222	
$\pi$ $\omega$	:
	ı
94 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9	:
	;
0	:
H	
999915566666666666666666666666666666666	
	•
	•
` <i>ᲐᲑᲡᲐᲑᲐᲑᲐᲑᲐᲑᲐᲑᲐᲑᲐ</i> ᲑᲐᲛᲐᲛᲐᲛᲐᲛᲐᲛᲐ	